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A B S T R A C T
Background
Primary prevention programmes in many countries attempt to reduce mortality and morbidity due to coronary heart disease (CHD)
through risk factor modification. It is widely believed that multiple risk factor intervention using counselling and educational methods
is efficacious and cost-effective and should be expanded. Recent trials examining risk factor changes have cast considerable doubt on
the effectiveness of these multiple risk factor interventions.
Objectives
To assess the effects of multiple risk factor intervention for reducing cardiovascular risk factors, total mortality, and mortality from
CHD among adults without clinical evidence of established cardiovascular disease.
Search strategy
MEDLINE was searched for the original review to 1995. This was updated by searching the Cochrane Central Register of Controlled
Trials on The Cochrane Library Issue 3 2001, MEDLINE(2000 to September 2001) and EMBASE (1998 to September 2001).
Selection criteria
Intervention studies using counselling or education tomodifymore thanone cardiovascular risk factor in adults fromgeneral populations,
occupational groups, or high risk groups. Trials of less than 6 months duration were excluded.
Data collection and analysis
Data were extracted by two reviewers independently. Investigators were contacted to obtain missing information.
Main results
A total of 39 trials were found of which ten reported clinical event data. In the ten trials with clinical event end-points, the pooled odds
ratios for total and CHDmortality were 0.96 (95% confidence intervals (CI) 0.92 to 1.01) and 0.96 (95% CI 0.89 to 1.04) respectively.
Net changes in systolic and diastolic blood pressure, and blood cholesterol were (weighted mean differences) -3.6 mmHg (95% CI -3.9
to -3.3 mmHg), -2.8 mmHg (95% CI -2.9 to -2.6 mmHg) and -0.07 mMol/l (95% CI -0.8 to -0.06 mMol/l) respectively. Odds of
reduction in smoking prevalence was 20% (95% CI 8% to 31%). Statistical heterogeneity between the studies with respect to mortality
and risk factor changes was due to trials focusing on hypertensive participants and those using considerable amounts of drug treatment.
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Authors’ conclusions
The pooled effects suggest multiple risk factor intervention has no effect on mortality. However, a small, but potentially important,
benefit of treatment (about a 10% reduction in CHD mortality) may have been missed. Risk factor changes were relatively modest,
were related to the amount of pharmacological treatment used, and in some cases may have been over-estimated because of regression
to the mean effects, lack of intention to treat analyses, habituation to blood pressure measurement, and use of self-reports of smoking.
Interventions using personal or family counselling and education with or without pharmacological treatments appear to be more
effective at achieving risk factor reduction and consequent reductions in mortality in high risk hypertensive populations. The evidence
suggests that such interventions have limited utility in the general population.
P L A I N L A N G U A G E S U M M A R Y
Multiple risk factor interventions for primary prevention of coronary heart disease
In many countries, there is enthusiasm for “Healthy Heart Programmes” that use counseling and educational methods to encourage
people to reduce their risks for developing heart disease. These risk factors include high cholesterol, excessive salt intake, high blood
pressure, excess weight, a high-fat diet, smoking, diabetes, and a sedentary lifestyle. This updated review of all relevant studies found
that the approach of trying to reduce more than one risk factor - multiple risk factor intervention - advocated by these Programmes do
result in small reductions in blood pressure, cholesterol, salt intake, weight loss, etc. Contrary to expectations, these lifestyle changes
had little or no impact on the risk of heart attack or death. Possible explanations for this are that the small risk factor changes are not
maintained long-term or are not real but caused by some of the studies being poorly conducted. This review is based on the findings
from 39 trials conducted in several countries over the course of three decades. Its authors discourage more research on the topic: “Our
methods of attempting behaviour change in the general population are very limited. Different approaches to behaviour change are
needed and should be tested empirically before being widely promoted. For example, the availability of foods and better access to
recreational and sporting facilities may have a greater impact on dietary and exercise patterns respectively, than health professional
advice.”
B A C K G R O U N D
In apparently healthy and asymptomatic people, the incidence of
cardiovascular disease is in part explained by the modifiable risk
factors: serum total cholesterol and reduced high density lipopro-
tein (HDL) cholesterol, blood pressure, cigarette smoking and di-
abetes. Primary prevention programmes attempt to reduce coro-
nary heart disease (CHD) mortality and morbidity through risk
factor modification. While the identification of high risk individu-
als and treatment according to level of cardiac risk may be effective
at an individual level, population strategies may be more effective
in reducing the burden of cardiovascular disease (Emberson 2004).
Recent findings suggest that increasingly effective drug treatments
for high risk individuals and widespread implementation of pop-
ulation wide strategies of tobacco control and dietary changes is
increasing the advantage of high risk approaches to prevention.
(Jackson 2006)
In the UK, the National Service Framework for coronary heart
disease promotes multiple risk factor counselling and health edu-
cation (NSF-CHD 2000). In the USA, the AHA Guidelines for
Primary Prevention of Cardiovascular Disease and Stroke: 2002
update identify areas for intervention based on the non-pharmaco-
logical treatment of established risk factors (AHA 2002). Similarly,
the Third Joint Task Force of the European and other Societies
recommend use of behavioural counselling for stopping smoking
tobacco, making healthy food choices and increasing physical ac-
tivity (ESC 2003).
Primary prevention programmes in many countries attempt to
reduce mortality and morbidity due to coronary heart disease
through risk factor modification (Canadian 1986; Kickbush
1988). Randomized controlled trials of the efficacy ofmultiple risk
factor intervention using counselling and education in addition
to, or instead of, pharmacological treatments to modify major car-
diovascular risk factors have been carried out in primary care and
in the work place. The findings of these trials have been equivo-
cal; efficacy in reducing disease incidence appears to be associated
with the degree of risk factor control achieved (Editorial I 1982;
Editorial II 1982). Taken with evidence from quasi-experimen-
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tal studies, such as the North Karelia project (Puska 1976; Puska
1981) and the Stanford Heart Disease Prevention Programme
(Farquhar 1977; Farquhar 1990; Fortmann 1993), it was widely
believed that multiple risk factor intervention using counselling
and educational methods was efficacious and cost-effective and
should be expanded.
Along side this research health services have acted by developing
health promotion as a specialty (Editorial 1984), organising the
routine collection of data on cardiovascular risk factors in British
primary care, and issuing primary prevention policy, for example
the Health of the Nation strategy in England (DoH 1992). More
recent trials examining risk factor changes have cast considerable
doubt on the effectiveness of these multiple risk factor interven-
tions (Stott 1994a; Stott 1994b) and even interventions specifi-
cally against smoking (COMMIT I 1995; COMMIT II 1995)
prompting a review of the reasons for the frequent failure of such
community experiments (Susser 1995). A new generation of pop-
ulation based interventions such as the Minnesota Heart Health
Program (Luepker 1994), Heartbeat Wales (Tudor-Smith 1998),
the Malmö preventive project (Berglund 2000) have cast further
doubt on the value of such interventions.
Treatment ofmultiple risk factors by dietmodification, promotion
of physical activity, weight loss and smoking cessation has been
evaluated in a number of randomised trials. Two previous reviews
(McCormick 1988; Schoenberger 1990) of multiple risk factor in-
tervention using counselling and education with or without phar-
macological treatments were conducted prior to the publication
of more recent trials, were not systematic in their coverage, and
did not formally aggregate the findings through meta-analysis.
In a systematic review, fourteen randomised trials were identified
up until April 1995. Meta-analyses suggested that although inter-
ventions achieved reductions in risk factors, these were small and
were not translated into significant decreases in morbidity or mor-
tality (Ebrahim 1997). Since this systematic review was published
a number of trials of multiple risk factor interventions have been
reported and update of the review is needed.
O B J E C T I V E S
To assess the effectiveness of multiple risk factor intervention us-
ing counselling and/or educational approaches with or without
pharmacological interventions in:
a) reducing systolic and diastolic blood pressure;
b) reducing blood cholesterol levels;
c) reducing smoking rates;
d) reducing total mortality;
e) reducing CHD mortality;
among middle-aged (40+) adults.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized controlled trials of at least 6 months duration with
parallel group design. Trials may be randomized by individual or
by group (e.g. family, workplace site).
Types of participants
Adults aged at least 40 years old.
General populations, workforce populations and high risk groups.
Participants without clinical evidence of cardiovascular diseases.
Types of interventions
Counselling or educational interventions, with or without phar-
macological treatments, which aim to reduce more than one car-
diovascular risk factor (i.e. blood pressure, smoking, total blood
cholesterol, physical activity, diet).
Types of outcome measures
Total mortality, CHD mortality, net change in blood pressure,
smoking and total blood cholesterol.
Search methods for identification of studies
MEDLINE was searched from 1966 to April 1995 using an RCT
filter (Dickersin 1994,) together with relevant diagnostic terms
(i.e. coronary heart disease and stroke) and text word searches for
specific interventions (e.g. dietary change, smoking cessation, ex-
ercise, blood pressure control, prevention, cholesterol lowering).
Searches of reference lists of papers, expert advice and use of cita-
tion searches. This was updated by searching the Cochrane Cen-
tral Register of Controlled Trials (CENTRAL) on the Cochrane
Library Issue 3 2001, MEDLINE (2000 to September 2001)
and EMBASE (1998 to September 2001),using an RCT filter for
MEDLINE (Dickersin 1994) and EMBASE ( Lefebvre 1996). See
additional tables for details of search strategies (Table 1; Table 2;
Table 3; Table 4).
Strategy used for searching The Cochrane LIbrary:
#1 CARDIOVASCULAR DISEASES
#2 CORONARY DISEASE
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#3 cardiovascular
#4 (coronary near disease*)
#5 (heart near disease*)
#6 HYPERTENSION
#7 hypertension
#8 (atherosclerosis or arteriosclerosis)
#9 (hyperlipidaemia or hyperlipidemia)
#10 ARTERIOSCLEROSIS
#11 CHOLESTEROL
#12 HYPERLIPIDEMIA
#13 cholesterol
#14 (multiple next risk next factor*)
#15 (coronary next risk next factor*)
#16 (#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10)
#17 (#11 or #12 or #13 or #14 or #15)
#18 (#16 or #17)
#19 HEALTH EDUCATION
#20 HEALTH PROMOTION
#21 HEALTH BEHAVIOR
#22 PRIMARY PREVENTION
#23 COUNSELING
#24 counsel*
#25 (health near educat*)
#26 (patient near educat*)
#27 (education* near program*)
#28 (health near promotion*)
#29 (health near behaviour*)
#30 (health near behavior*)
#31 (primary next prevention)
#32 ((multiple next risk) near intervention*)
#33 (multifactor* near intervention*)
#34 (multifactor* near prevention)
#35 ((risk next factor*) near reduc*)
#36 ((risk next factor*) near manag*)
#37 ((risk next factor*) near intervent*)
#38 (lifestyle near intervention*)
#39 (lifestyle near advice)
#40 (life-style near intervention*)
#41 (life-style near advice)
#42 (life-style near alter*)
#43 (lifestyle near alter*)
#44 (lifestyle near educat*)
#45 (life-style near educat*)
#46 (life-style near chang*)
#47 (lifestyle near chang*)
#48 (behavior* near chang*)
#49 (behaviour* near chang*)
#50 ((health next care) near advice)
#51 (healthcare near advice)
#52 nonpharmacologic*
#53 non-pharmacologic*
#54 (#19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #
27 or #28 or #29)
#55 (#30 or #31 or #32 or #33 or #34 or #35 or #36 or #37 or #
38 or #39)
#56 (#40 or #41 or #42 or #43 or #44 or #45 or #46 or #47 or #
48 or #49 or #50 or #51 or #52 or #53)
#57 ((#54 or #55 or #56)
#58 (#18 and #57)
Data collection and analysis
For the original search titles and abstracts obtained through
searches were checked by two reviewers. Each paper thought to
be of possible relevance was obtained and read by each reviewer
independently to determine whether it fitted specified inclusion
criteria. Disagreements were discussed and resolved between the
two reviewers. The results of the updated search were checked by
one reviewer to eliminate those studies that were definitely not
relevant to the review. Remaining records were checked by two
reviewers independently. All papers that were thought to be of
relevance were obtained and read by two reviewers independently.
Disagreements were resolved by discussion or by consultation with
a third reviewer. The main aspect of quality that was formally as-
sessed was the adequacy of concealment of randomisation as other
aspects (e.g. blinding) are of less relevance in non-pharmacological
interventions. In addition, comparability of baseline characteris-
tics and completeness of follow up were assessed.
Independent data abstraction was performed and chief investi-
gators were contacted to provide additional relevant information
where necessary.
For continuous variables, net changes were compared (i.e. control
group minus intervention group differences) at the longest dura-
tion of follow up available and the standardised mean difference
were examined using random and fixed effects model. Categorical
variables (mortality rates) were expressed as odds ratios and fixed
effect models used except where there was significant heterogene-
ity of effects.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
Details of the studies included in the review are shown in the table
of characteristics of included studies.
Risk of bias in included studies
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The quality of the trials examined deserves comment. Very few
of the published reports provided sufficient detail to replicate the
intervention used, and in several trials the intervention varied be-
tween sites and over time. It is likely that the quality of the inter-
vention, in terms of intensity and frequency, person carrying out
activities, and the theoretical framework of behavioural change
used will determine the impact of intervention. Losses to follow
up were a particular problem as changes in risk factors cannot be
assessed in an intention to treat analysis. Validation of smoking
outcomes using biochemical assay of cotinine was only used in
one trial.
Random allocation methods were not usually reported in the
smaller trials and specific enquiries were not made of investigators.
In the large trials, it is unlikely that the allocation method was
suspect. Blinding of intervention allocation is not possible in life-
style interventions and this inevitably raises the possibility of bias.
Outcomes were usually assessed with knowledge of treatment al-
location and this too makes biased assessment of some outcomes
possible. It seems unlikely that lack of blinding had any effect on
clinical event outcomes, but it is possible that participants ran-
domised to a control or usual care group might have been more
likely to take health preventive activity as they may have felt they
were missing potential benefits. Lack of blinding in assessment
of smoking histories may have resulted in a reporting bias with
those allocated to interventionsmore likely to say they had stopped
smoking. Validation of self-reported smoking outcomes using bio-
chemical assay of serum thiocyanate was reported in three trials.
Effects of interventions
Details of the studies included in the review are shown in Table
1. A total of 39 trials of multiple risk factor intervention were
found comprising 44 distinct study groups. This is more than
double the 18 trials identified for the original review. Ten trials
reported total or coronary heart disease mortality as outcomes but
none of these were additional to those in the original review. One
trial from the original review, the Swedish RIS study, reported
extended mortality follow up. Only four trials were sufficiently
large to have adequate power to show meaningful changes in total
or coronary heart disease mortality. More recent trials focussed on
the outcomes: blood pressure, serum cholesterol, physical activity,
diet, control of diabetes and weight loss. In the original review
eleven studies reported smoking habit as an outcome. Among the
newly identified trials only a further three reported an outcome
relating to smoking cessation.
In more recent trials the quality of reporting was noticeably im-
proved. It was noted in the original review that few early trials pro-
vided sufficient detail to replicate the intervention used and that
several studies reported interventions that varied between sites and
over time.
In general, the trials compared an intervention comprising some
form of counselling and education with control groups, which ei-
ther received nothing or usual care. The type of behavioural inter-
vention used was seldom reported. In the few studies reporting the
type of intervention a Stages of Change model ( Diclemente 1991;
Prochaska 1983) and a person centred and self directed psycho-
logical approach (Meichenbaum 1993) were described. In trials
included in the review, education and counselling targeted combi-
nations of diet, exercise, weight loss, smoking cessation, diabetes
management and use of medication.
With the exception of one study comprising men andwomen aged
60-85 years (Applegate 1992), the oldest subjects included in the
trials were 75 years of age. The majority of trials randomised only
middle-aged adults and some included younger adults. One trial
was not included in analyses (Connell 1995) as losses to follow up
were extremely high.
Sixty seven trials identified as involving multiple risk factor in-
terventions were excluded from consideration for the following
reasons: no risk factor changes measured and/or reported (n=9),
non-random or inadequate allocation to intervention and control
groups (n=21), no specific multiple risk factor intervention (n=3),
control group received substantial intervention (n=17), follow up
to 6 months was not reported (n=6), the mean age of participants
was less than 40 (n=5), a substantial proportion of participants
had heart disease (n=3), numbers in groups were not reported (n=
1), or baseline or follow up data were not provided (n=2). A large
number of studies were set up in what was then the Soviet Union
but it appears that allocation to intervention and control groups
was not random although attempts to trace the investigators have
been unsuccessful.
The trials with clinical end-points comprise approximately
903,000 patient years of observation and those with risk factor
end-points had 303,000 patient-years of observation. The oldest
subjects included in any of the trials were less than 74 years of age,
with the majority of trials randomising only middle-aged adults.
Total mortality and coronary heart disease mortality
Ten trials reported total and coronary heart disease mortality out-
comes. For total mortality there was a pooled odds ratio of 0.96
(95% CI 0.92 to 1.01) favouring intervention. With regard to
coronary heart disease mortality the odds ratio favouring inter-
vention was 0.96 (95% CI 0.89 to 1.04). Funnel plots suggested
little evidence of small study bias in trials with these outcomes
(Figure 1; Figure 2). Only the Hypertension Detection and Fol-
low-up Program, Johns Hopkins Hypertension Trial and Swedish
RIS reported significant effects on total mortality (HDFP trial,
Johns Hopkins, Swedish RIS). The Johns Hopkins Hypertension
Trial also showed a significant benefit for coronary heart disease
mortality.
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Figure 1.
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Figure 2.
Evidence of statistical heterogeneity was apparent in the pooled
odds ratios for total mortality but not for coronary heart disease
mortality when all studies were included. Removal of the trials
including hypertensives (HDFP trial; Johns Hopkins) reduced the
heterogeneity for total mortality. Including a term for interaction
between treatment effect and baseline level of coronary heart dis-
ease risk calculated using either control group coronary heart dis-
ease risk or combined control and intervention group risk reduced
heterogeneity between the trials to insignificant levels for total and
coronary heart disease mortality.
Modelling the effects of age using the mean age of study partic-
ipants and proportion of patients on antihypertensive treatment
and cholesterol lowering drug treatment did not reveal any signifi-
cant interactions between age, drug treatments and outcome. The
significant interaction between intervention and level of coronary
heart disease risk indicated that trials recruiting higher risk par-
ticipants were more likely to demonstrate beneficial effects. This
effect is explained by the inclusion of the two trials which studied
hypertensive patients rather than general population or workforce
subjects. It is impossible to separate this effect of baseline coronary
heart disease risk from the benefits of pharmacological treatment
of hypertension.
Non-fatal myocardial infarctions were reported in the WHO Fac-
tory Study, the Gothenberg Study and in the Oslo Study (WHO
Factories; Gothenberg Study;The Oslo Study). The pooled odds
ratio for non-fatal myocardial infarction in these three trials was
1.01 (95% CI 0.93 to 1.10).
Changes in risk factors
In all but five of the trials reporting systolic blood pressure as an
outcome there was a tendency for reduced systolic blood pressure
in intervention groups. Changes in blood pressure were small and
slightly less in the updated compared with the original review.
In 38 interventions reporting systolic blood pressure change, the
weighted mean difference between intervention and control was
-3.6 mm Hg (95% CI -3.9 to -3.3) in fixed effect analysis. For
diastolic blood pressure the weighted mean difference was -2.8
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mm Hg (95% CI -2.9 to -2.6). For both outcomes there was no
evidence of small study bias in the trials as shown by the funnel
plots (Figure 3; Figure 4; Figure 5; Figure 6).
Figure 3.
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Figure 4.
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Figure 5.
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Figure 6.
The Multiple Risk Factor Intervention Trial, the Hypertension
Detection and Follow Up Program, theWHO factories study, the
Gothenburg study and the Finnish Businessmen study used anti-
hypertensive drug therapy if indicated (Finnish men; Gothenberg
Study; HDFP trial; MRFIT Study; WHO Factories). Exclusion
of those trials in which a high proportion of participants were
on pharmacological treatment (CELL Study; Gothenberg Study;
Finnish men; HDFP trial; MRFIT Study; Perez-Stable prop) re-
sulted in smaller, but still statistically significant, net reductions in
blood pressure: systolic -2.7 mmHg (CI -3.9 to -3.3), diastolic -
1.7 mmHg (CI -2.0 to -1.5).
Not all trials reported, or were able to provide data on, blood pres-
sure at follow up. Investigators from the Oslo study stated that
there were no changes observed (Hjerman I. personal communi-
cation, 1996).
Blood cholesterol
Blood cholesterol levels showed a small but highly significant fall
(net difference -0.07 mmol/L, 95% CI -0.08 to -0.06 mmol/L).
This was half the fall seen in the earlier review andmay reflectmore
widespread use of cholesterol lowering medication in recent years.
Substantial heterogeneity was apparent in this meta-analysis.
The Hypertension Detection & Follow-up Program reported no
reduction in blood cholesterol levels but published quantitative
data are not available (HDFP trial). The Finnish Businessmen
Trial made substantial use of cholesterol lowering drugs (mainly
probucol and clofibrate) which probably explains the larger reduc-
tion in blood cholesterol observed in this trial (Finnish men). In
the FARIS trial there was a mean reduction in cholesterol of 3.0
mmol/L inmen randomised tomultifactorial intervention (FARIS
men; FARIS women). This is probably a consequence of statin
prescription being recommended after 3 months of intervention
if cholesterol control was not adequate by lifestyle modification.
Exclusion of these trials did not make a difference to the pooled
fall observed.
Smoking
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Smoking prevalence showed an overall net reduction of 24%. Sub-
stantial heterogeneity was apparent and an odds reduction of 20%
was observed in a random effects model. In the Hypertension De-
tection & Follow up Program quantitative data were not avail-
able but no changes in smoking rates were found (HDFP trial).
Smoking rates fell particularly sharply in the Multiple Risk Factor
Intervention Trial and in the Oslo Study which both used indi-
vidual smoking advice given by a physician (MRFIT Study; The
Oslo Study) and in the Change of Heart study where large base-
line differences between groups were noted and losses to follow
up were high (Change of Heart study). Validation of self-reported
smoking rate reductions in the Multiple Risk Factor Intervention
Trial by comparison with serum thiocyanate levels suggested that
the improvement might be overestimated (MRFIT Study).
Heterogeneity of effects
Blood pressure, smoking, and blood cholesterol outcomes were
subject to substantial heterogeneity. Random effects analyses were
also conducted which showed similar pooled net effects but as the
variation between trials is taken into account (which is large), con-
fidence intervals were wider. The heterogeneity between trials is
probably explained by differences in the use of both antihyperten-
sive and cholesterol-lowering drugs, and the populations studied.
Risk factor net changes were strongly correlated with the initial
level of diastolic blood pressure, smoking and blood cholesterol
but not systolic blood pressure. The sample size weighted correla-
tion coefficients between initial level and magnitude of risk factor
reduction for diastolic blood pressure, smoking and blood choles-
terol were 0.73, p=0.006, 0.63, p=0.01 and 0.74, p=0.004 re-
spectively. Those studies with the highest baseline diastolic blood
pressure, smoking prevalence and blood cholesterol levels demon-
strated larger intervention associated falls in these risk factors.
Cluster-randomisation
In meta-analysis the weighting given to trials with a cluster design
may be over-estimated. In trials with cluster design analysed by
individual or by cluster there was no evidence of overall benefit
with regard to lowering of blood pressure or cholesterol. Benefits
tended to be in trials with randomisation by individual.
D I S C U S S I O N
Findings
As reported in the earlier review, multiple risk factor interven-
tions comprising counselling, education and drug therapies were
ineffective in achieving reductions in total or cardiovascular dis-
ease mortality when used in general or workforce populations of
middle-aged adults. The pooled effects of intervention were sta-
tistically insignificant but a potentially useful benefit of treatment
(about a 10% reduction in coronary heart disease mortality) may
have been missed.
The risk factor changes associated with interventions were mod-
est, but are probably optimistic estimates as changes could only be
measured in those remaining in the trials. Habituation to blood
pressure measurement, regression to the mean, and self-reports of
smoking will also tend to exaggerate the changes observed. It is,
however, not possible to separate participants’ level of risk from
the use of anti-hypertensives in the present set of trials, as studies
with high-risk participants tended to be the ones which included
participants with high levels of anti-hypertensive drug use. Fur-
thermore, there are many problems in relating trial outcome to a
risk measure which is itself dependent on the outcome in meta-
analysis (Egger 1995). Therefore our conclusions on these issues
can only be tentative.
Heterogeneity of intervention effects is apparent. This is probably
caused by two factors: the participants included in the trials, and
the use of pharmacological treatments. Hypertensives, at highest
risk, were more likely to benefit from counselling and education,
and effective drugs. These findings suggest that targeting of current
health promotion activities to high risk individuals might be of
more value than more general health promotion for everyone.
The interventions used
The benefits of drug treatments for lowering blood pressure and
cholesterol are clear (Collins 1994; Davey Smith 1993; CTT
2005). However, those people at highest risk of disease in both
hypertension control (Mulrow 1995) and cholesterol lowering
(Davey Smith 1993) benefit most. Treatment of low risk popu-
lations may result in small treatment benefits being outweighed
by small treatment risks (Davey Smith 1994) which may have oc-
curred in both the Multiple Risk Factor Intervention Trial and the
Finnish businessmen’s trial (Finnish men; MRFIT Study). There
were strong associations between baseline levels of risk factors and
net falls experienced, suggesting that intervention may be more
effective in populations with particularly adverse risk factor pro-
files.
More intensive interventions might be expected to produce bet-
ter effects although those used in many of the trials would far
exceed what is feasible in routine practice. A meta-analysis of di-
etary modifications found that increasing intensity of dietary in-
tervention was associated with greater falls in blood cholesterol
levels in high risk participants (Brunner 1997). In the Minnesota
Heart Health Programme, a non-randomised community trial of
intensive health promotion, both risk-factor andmortality changes
showed virtually no difference between intervention and con-
trol communities (Luepker 1996). The continued enthusiasm for
health promotion practices given the failure of these community
intervention trials is curious, especially given the huge resources
which have been put into them.
Latency of effects
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It is possible that benefits cannot be detected in the early stages
but emerge over time. Longer term follow up of the Multiple
Risk Factor Intervention Trial participants has demonstrated in-
creased divergence between control and intervention group mor-
tality rates (MRFITRG 1990) which has also been found in the
Tromso Family Trial (Professor S. Knutson, personal communi-
cation). However, evidence from pharmacological trials suggests
benefits from reduction of blood pressure and blood cholesterol
are observed within two to four years (Collins 1994; Scandanavian
1994). The effects of giving up smoking vary depending on the
clinical outcome considered: stroke risk falls rapidly after stopping
(Wannamethee 1995), but coronary heart disease risk may be less
reversible (Ben-Shlomo 1994; Cook 1986).
Evidence of benefit
The quasi-experimentalNorthKarelia study has been very influen-
tial in supporting multiple risk factor intervention. Examination
of the trends in both risk factors (Puska 1985; Vartiainen 1994)
and coronary heart disease mortality (Valkonen 1992) observed
in North Karelia and comparison regions show similar patterns
occurring at the same time, suggesting that the interventions in
North Karelia were not instrumental in causing the improvements
observed (Ebrahim 2001). Indeed, the North Karelia and similar
projects may be viewed as effects, or epiphenomena, of the very
high coronary heart disease mortality rates experienced in many
countries in the 1960s.
In secondary prevention following myocardial infarction and
angina, trials of multiple and single risk factor interventions have
suggested substantial benefits ( Mullen 1992; Oldridge 1988;
O’Connor 1989). It is probable that intervention aimed at life-
style modification following myocardial infarction is effective be-
cause participants aremuchmore likely to change their behaviours.
Limitations of randomised controlled trials
The interventions reviewed were essentially individual or family
approaches. Randomised controlled trials impose limitations on
the nature of interventions that may be tested and are of more
value in examining high risk rather than population and social
approaches to prevention (Rose 1992).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The use of “health promotion” techniques of one-to-one or family
orientated information and advice on a range of life-styles (exer-
cise, smoking cessation, diet) given to people at relatively low risk
of cardiovascular disease is not particularly effective in terms of
reducing the risk of clinical events. The costs of such interventions
are high and it seems likely that these resources and techniques
may be better used in people at high risk of cardiovascular disease
where evidence of effectiveness is much stronger.
Policy implications
Health protection through national fiscal and legislative changes
that aim to reduce smoking, dietary consumption of fats, “hidden”
salt and calories, and increase facilities and opportunities for ex-
ercise should have a higher priority than health promotion inter-
ventions applied to general and workforce populations. It is essen-
tial that the current concepts and practices of multiple risk factor
intervention, primarily through individual risk factor counselling,
are not exported to poorer countries as the best policy option for
dealing with existing and projected burdens of cardiovascular dis-
ease, as is currently happening (Pearson 1993). Health protection
should be promoted as the mainstay of chronic disease prevention
in poorer countries (Ebrahim 2001).
Implications for research
It is unlikely that any further large-scale multiple risk factor in-
tervention trials will be mounted in high income countries in the
future. It is also unlikely that uncontrolled or quasi-experimental
study designs will produce more robust answers to questions of
the effectiveness of multiple risk factor intervention by means of
individual or family health information and advice.
Research on the effects and costs of health protection (i.e. fiscal and
legislative approaches) and primary prevention would be of direct
policy relevance, particularly in low and middle income countries.
Qualitative studies examining how participants perceived and re-
sponded to the advice and treatment given in these randomised
controlled trials could be very helpful in shaping future interven-
tions.
Our methods of attempting behaviour change in the general pop-
ulation are very limited. Different approaches to behaviour change
are needed and should be tested empirically before being widely
promoted. For example, the availability of foods and better access
to recreational and sporting facilities may have a greater impact
on dietary and exercise patterns respectively, than health profes-
sional advice. The effects of new approaches need to be examined
in a wide range of people as it seems likely that the poor, socially
excluded, specific ethnic groups and older people may all react in
different ways.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Aberg men
Methods Primary care. Random allocation by health centre (centres paired according to size, number of doctors and personnel)
. Unit of analysis was individual
Participants Men and women on anti-hypertensive drugs aged 30-69 years
N=159
Interventions Group based video taped lifestyle counselling: Dietary change, stress management, increased physical activity. home
blood pressure monitoring.
Up to 8 group sessions.
Outcomes No clinical event outcomes. Change in anti-hypertensive treatment, weight, hypertension, cholesterol, triglycerides,
fasting glucose, life quality
Notes All patients followed the same schedule for reduction and withdrawal of antihypertensive drugs.
Concluded that intervention was effective in reducing hypertensive medication
Aberg women
Methods Primary care. Random allocation by health centre (centres paired according to size, number of doctors and personnel)
. Unit of analysis was individual
Participants Men and women on anti-hypertensive drugs aged 30-69 years
N=129
Interventions Group based video taped lifestyle counselling: Dietary change, stress management, increased physical activity. home
blood pressure monitoring.
Up to 8 group sessions.
Outcomes No clinical event outcomes. Change in anti-hypertensive treatment, weight, hypertension, cholesterol, triglycerides,
fasting glucose, life quality
Notes All patients followed the same schedule for reduction and withdrawal of antihypertensive drugs.
Concluded that intervention was effective in reducing hypertensive medication
Abingdon
Methods Primary care
Random allocation by individual
Participants Men and women, mean age 42 years (range 25-60)
N=368
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Abingdon (Continued)
Interventions Diet, weight control, smoking advice, exercise, alcohol advice carried out by nurse
Duration 1 year
Outcomes No clinical event outcomes
Systolic blood pressure, diastolic blood pressure, blood cholesterol, smoking prevalence
Notes Main focus was on dietary change, but despite self reported behaviour change, no changes in blood cholesterol found
Applegate 1992
Methods Community screening and volunteers
Randomisation by individual
Participants Men and women aged 60-85 with mild diastolic hypertension and modestly overweight
N=56
Interventions Nutritionist supervised.
Individual weight loss goals, exercise and diet self-monitoring with behavioural feedback.
Duration 6 months
Outcomes No clinical event outcomes. Weight, urinary sodium, systolic and diastolic blood pressure, waist-hip ratio, exercise
Notes Reduction in weight and systolic blood pressure in those folowed up. Authors report good compliance with inter-
vention. Authors conclusions: results indicate intervention will lower borderline or mild diastolic hypertension
Blumenthal 2000
Methods Volunteers screened
Randomisation by individual
Participants Men and women aged 29+ with unmedicated high-normal blood pressure.
Overweight and not performing regular aerobic exercise. N=79
Interventions Exercise physiologist supervised exercise and behavioural intervention including diet. Duration 6 months
Outcomes No clinical event outcomes
Systolic and diastolic blood pressure, glucose tolerance, weight, exercise test
Notes Another intervention group received only exercise intervention. Authors conclusions: Exercise alone reduced BP and
the addition of behavioural weight loss programme enhanced this
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CELL Study
Methods Primary care screening
Randomisation of individuals in 2x3 factorial design
Participants People with at least two risk factors in addition to moderately raised blood cholesterol
Men and women, mean age 49 years (30-59)
N=681
Interventions Factor 1: Counselling on health problems and risk factor management, food purchasing, exercise vs. usual care
Factor 2: Pravastatin vs. placebo vs control without drug
Duration 1 year
Outcomes Total mortality and CHD mortality
Systolic blood pressure, diastolic blood pressure, blood cholesterol, smoking prevalence, exercise score
Notes At one year counselling intervention main effects showed lower blood cholesterol and lower Framingham risk factor
scores compared with groups not receiving counselling intervention. No significant differences in blood pressures,
smoking prevalence, or exercise score
Change of Heart
Methods General practice, cluster allocation by minimisation to balance for social deprivation, practice nurse hours and
fundholding status. 20 practices. Unit of analysis was general practice
Participants Men and women mean age 47 years with one or more cardiovascular risk factors. No treatment. N=883
Interventions Nurse led stages of change behavioural counselling on smoking, diet, physical activity. 2 or 3 20 minute counselling
sessions + telephone contact
Outcomes No clinical event outcomes. Diet, exercise, smoking habits, blood pressure, cholesterol, weight, BMI
Follow up 4 and 12 months
Notes Based on stages of change model. Less smokers at baseline in intervention group (39%) than control (49%)
Problems with recruitment and dropout - more recruited to intervention than control group - 59% of patients
followed up at 12 months. Those at higher risk received more intensive treatment
Connell 1995
Methods Worksite volunteers
Randomisation by worksite. Unit of analysis was individual
Participants Men and women age 19-67
N=1432
Interventions Health risk assessment and individual health counselling
Educational classes and self-help material
Duration 1 year
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Connell 1995 (Continued)
Outcomes Total cholesterol, systolic and diastolic blood pressure, BMI, exercise frequency
One year follow up
Notes Large loss to follow up
Family Heart - men
Methods Primary care
Random allocation of households to intervention and control groups
Participants Primary care screening, mean age 50 (40-59)
N=3941
Interventions Intensity of intervention depended on individual’s level of risk.
Nurse counselling on diet, weight, smoking, exercise, alcohol
Duration 1 year
Outcomes No clinical event outcomes
Systolic blood pressure, diastolic blood pressure, blood cholesterol, smoking prevalence
Notes Two control groups used: internal to study used for comparisons in this review. Drop outs were more likely to have
high CVD risk factor levels. Overall predicted risk reduction of 12% achieved but thought to be too costly in practice
- no cost-effectiveness analysis conducted however
Family Heart - women
Methods Primary care
Random allocation of households to intervention and control groups
Participants Primary care: women age 50 (40-59)
N=2619
Interventions Intensity of intervention depended on level of individual’s risk
Nurse counselling on diet, weight control, smoking advice, exercise, alcohol
Duration 1 year
Outcomes No clinical event outcomes
Systolic blood pressure, diastolic blood pressure, blood cholesterol, smoking prevalence
Notes Two control groups used but internal control used in this review
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FARIS men
Methods First degree relatives of AMI, CABG and PTCA patients
Randomised by family.
Participants Families of people with CHD event, age 18-69,
N=442
Interventions Individualised risk factor advice. 3 months dietary advice and lipid lowering medication if required
Outcomes No clinical event outcomes
Systolic blood pressure
diastolic blood pressure, cholesterol, smoking, BMI and CVD risk
Notes Results are for people without cardiovascular disease attending combined primary and secondary prevention clinic.
Information on baseline and follow up smoking prevalence not available. No significant effect of intervention on
smoking quit rate
FARIS women
Methods First degree relatives of AMI, CABG and PTCA patients
Randomised by family.
Participants Families of people with CHD event, age 18-69,
N=658
Interventions Individualised risk factor advice. 3 months dietary advice and lipid lowering medication if required
Outcomes No clinical event outcomes
Systolic blood pressure
diastolic blood pressure, cholesterol, smoking, BMI and CVD risk
Notes Results are for people without cardiovascular disease attending combined primary and secondary prevention clinic.
Information on baseline and follow up smoking prevalence not available. No significant effect of intervention on
smoking quit rate
Finnish DPS
Methods High risk groups identified from epidemiological surveys, opportunistic screening, volunteers.
Randomisation by individual, stratified by sex, centre and OGTT result
Participants Overweight or with family history of type 2 diabetes men and women aged 40-64 years with impaired glucose
tolerance
N=523
Interventions Nutritionist delivered individual and group dietary advice. Weight goal established with physician and nutritionist
and reguar assessment. Supervised exercise. Each person had 7 sessions in the first year and one session every 3months
subsequently
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Finnish DPS (Continued)
Outcomes No clinical events outcomes. Development of diabetes, weight, diet, exercise, waist circumference, glucose, insulin,
cholesterol, HDL, triglycerides, systolic and diastolic blood pressure. Follow up reported end of year 1
Notes Study planned for 6 years, recruited 1993 to 1998. In March 2000 study stopped on basis of results regarding
reduction in incidence in diabetes in treatment group
Finnish men
Methods Volunteers recruited
Randomisation by individual
Participants Men only, mean age 48 years (40-58)
High risk
N = 1222
Interventions Diet, smoking, exercise, antihypertensive drugs, cholesterol lowering drugs
Duration 5 years
Outcomes Total mortality, CHD mortality
Systolic blood pressure, diastolic blood pressure, blood cholesterol, smoking prevalence
Notes Large reductions in blood pressure and blood cholesterol achieved largely through drug treatments, reductions in
smoking prevalence. Control group risk factors increased. CHD event rates higher in intervention group but stroke
rates significantly lower. Concluded that adverse effects of drug treatment may explain lack of benefit
Given 1984
Methods Primary care
Selection of hypertensives by screening
Randomisation of individuals
Participants Men and women with hypertension on a prescribed regimen of diet or medication, mean age 47 years (18-65)
N=86
Interventions Educational handbook on risk, impact and benefits of controlling hypertension. Individual problem solving sessions
on medication, diet and exercise.
Duration 6 months
Outcomes Systolic and diastolic blood pressure, weight, patient beliefs, symptom severity
Notes Authors note reduction in diastolic blood pressure. Intervention affected patient beliefs
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Gothenberg Study
Methods Population based
Selection of high risk people by screening
Randomisation of individuals
Participants Men only, mean age 51 years (47-55)
N=30,022
Interventions Diet, smoking, antihypertensive drugs, cholesterol lowering drugs
Duration 11.8 years
Outcomes Total mortality, coronary heart disease mortality
Systolic blood pressure, diastolic blood pressure, blood cholesterol, smoking prevalence
Notes Large falls in risk factors occurred in both intervention and control groups. Concluded that other strategies in high
risk men are required to have a major impact on incidence of disease in the general population
HDFP trial
Methods Population screening
Randomisation of individuals
Participants Men and women, all hypertensives, age range 30-69 years
N=10,940
Interventions Stepped care: Antihypertensive drugs, diet, smoking advice, weight control, exercise
vs. Referred care: usual primary care
Duration 5 years
Outcomes Total mortality, CHD mortality, Stroke mortality
Non-fatal CHD and stroke events
Diastolic blood pressure
Notes No reductions in smoking prevalence of blood cholesterol (data not published) but significant reductions in blood
pressure. Total mortality, CHD and stroke mortality significantly lower in intervention group. Benefits attributed to
treatment of high blood pressure and sustained over prolonged follow up
Hellenius
Methods Randomization of individuals in a 2x2 factorial design
Participants Men only, mean age 46 years (35-60)
Moderately raised CVD risk factors - already involved in a primary prevention programme
N=158
Interventions Diet and exercise advised
Duration 6 months
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Hellenius (Continued)
Outcomes No clinical event outcomes
Systolic blood pressure, diastolic blood pressure, blood cholesterol
Data also given on BMI, Waist/Hip ratio, HDL/LDL/VLDL cholesterol, tryglycerides, dietary intake, physical
activity
Notes Only data from control group (N=39) and diet and exercise group (N=39) used in this review
Iso
Methods Community screening. Randomisation by individual using permuted block method, stratified by blood pressure
Participants Untreated hypertensive men and women age 35-69 years
N=111
Interventions Physician, public health nurse and nutritionist led education, counselling and practical sessions. Individual goals for
sodium intake, weight control, walking and alcohol intake.
Duration 18 months
Outcomes No clinical event outcomes. Urinary sodium and potassium, sodium reduction behaviours, alchohol intake, calcium
intake, BMI, systolic and diastolic blood pressure
Notes Intervention associated with reduced systolic blood pressure, reduction in sodium excretion, alcohol consumption.
No change in BMI, diastoilc blood pressure. Greater use of anti-hypertensive medication in control group
Jalkanen 1991
Methods Patients from hypertension clinic
Randomisation of individuals
Participants Men and women, mean age 49 years (range 35-59)
With hypertension and overweight
N=50
Interventions Individually planned diet (1000-1500kcal per day)
Advice on exercise and weight reduction, weekly meetings for 6 months then 3 weekly.
Duration 12 months
Outcomes No clinical events outcomes.
Systolic and diastolic blood pressure, blood cholesterol, weight, food intake, urinary sodium and potassium
Notes Intervention led to reduction in weight
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Johns Hopkins
Methods Clinic attenders
Randomisation by individual to a complex factorial design with 8 groups
Participants Men and women, all hypertensives, mean age 54.1 years
N=400
Interventions Antihypertensive drugs, weight control, general health advice
vs. no extra educational interventions
Duration 5 years
Outcomes Total and CHD mortality
Notes Better control of blood pressure (but values not reported), weight and better adherence with treatment and appoint-
ments in intervention group. Concluded that educational programmes for hypertensive patients were beneficial
Lin 1996
Methods Primary care screening
4 villages randomly assigned. Unit of analysis was individual
Participants Men and women aged 40+ (mean 60)
N=1102
Interventions Home visits by public health nurse students aimed at weight reduction, physical activity, compliance with medication.
Trained volunteers and community leaders involved.
Education classes and speeches. Duration 6 months
Outcomes No clinical events outcomes. Blood pressure, behavioural changes
Notes Hypertensives received more intensive intervention
Lindahl 1999
Methods Participants in health survey screened for abnormal glucose tolerance
Participants Men and women with abnormal glucose tolerance and high BMI mean age 55
N=301
Interventions One month stay in full-board wellness centre. Scheduled aerobic physical activity, stress management, diet modifi-
cation, smoking cessation encouraged
Outcomes No clinical events outcomes. Systolic and diastolic blood pressure, cholesterol, fibrinolysis, BMI, physical fitness,
Follow up of 12 months
Notes Not all participants were followed up
Intense programme compared with usual care group
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Meland 1997
Methods Primary care opportunistic screening. Randomisation by general practice (N=22). Unit of analysis was individual
Participants Men aged 30-59 at high risk for CVD by infarction score
N=127
Interventions Counselling on health promotion and behaviour change. Self help and self monitoring.
Duration 1 year
Outcomes No clinical event outcome. Systolic and diastolic blood pressure, weight, resting pulse, cholesterol, lipid profile,
smoking habit, thiocyanate, C-peptide
Notes Kanfer and Gaelick (1986), and Meichenbaum (1986), person centred and self directed psychological approach.
Self efficacy was related to exercise change
MRFIT Study
Methods Worksite, population and volunteer screening
Randomisation by individual
Participants Men only, mean age 46 years (35-47)
N=12,866
Interventions Diet, smoking, weight, antihypertensive drugs
Duration 6 years
Outcomes Total mortality, coronary heart disease mortality
Systolic blood pressure, diastolic blood pressure, blood cholesterol, smoking prevalence
Notes Small reductions in blood cholesterol concentration. Large reductions in blood pressure and smoking rates. No
significant reduction in disease events. Concluded that possibly effective in sub-groups but no net benefit because of
potentially harmful effects of antihypertensive drugs used. Small benefits emerging after prolonged follow up
Nilsson 1992
Methods Randomisation of hyperinsulinaemics by individual within cross-sectional study of treated hypertensives and nor-
motensive controls
Participants Men and women, mean age 56.1 years with hyperinsulinaemia but not diabetic
N=59
Interventions Group education and individual counselling on diet and physical activity by nurse, dieticianand physiotherapist.
Duration 1 year
Outcomes Systolic and diastolic blood pressure, blood cholesterol, LDL/HDL cholesterol ratio, weight, waist hip ratio, blood
glucose, insulin, c-peptide, urate, glucose tolerance
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Nilsson 1992 (Continued)
Notes 63 randomised
Intervention group had reduced weight, waist hip ratio, blood pressure and LDL/HDL ratio. Also dietary improve-
ments.
Controls informed of hyperinsulinaemic status
Nilsson 2001
Methods Worksite screening
Randomisation by individual
Participants Men and women, mean age 50 years (range 28-65)
N=89
Interventions Multidisciplinary education and counselling. Weight reduction in obese, diet, physical activity, stress management,
smoking cessation
Duration 18 months
Outcomes Risk scores, BMI, waist hip ratio, sick days, sedentary behaviour, heart rate, smoking, CHD risk factors, glucose,
insulin, liver function, cortisol, dehydroepiandrosterone (DHEA)
Notes 128 randomised (Intervention group: 5 did not attend baseline, 16 dropouts or excluded for medical reasons at 12
months, 1 lost to followup at 18 month; control group corresponding figures 10, 5, 2 respectively)
Oldroyd
Methods People with impaired glucose tolerance identified in research studies, hospital databases and by GPs.
Randomisation by individual
Participants Men and women aged 24-75 years with impaired glucose tolerance identified in 2 OGTT
N=78
Interventions Dietician and physiotherapist counselling on diet and physical activity. Targets set by Stages of Change.
Duration 6 months
Outcomes No clinical event outcomes. Diet, aerobic physical activity, glucose tolerance, insulin sensitivity, blood pressure,
cholesterol, weight, BMI, waist hip ratio
Notes Intervention group showed increased physical activity, decreased fat consumption but no change in glucose tolerance
Oslo Diet Exercise
Methods Open, randomized 2x2 factorial design
Participants Men and women, mean age 40 years
N=219
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Oslo Diet Exercise (Continued)
Interventions Diet advice and supervised endurance exercise programme
Duration 1 year
Outcomes No clinical event outcomes reported
Systolic blood pressure, diastolic blood pressure, blood cholesterol
Also measured haemostatic factors, BMI, body weight, waist hip ratio, aerobic capacity, thiocyanate, triglycerides,
HDL/LDL cholesterol
Notes Comparison used in this review is between the control group (N=43) and the diet+exercise group(N=65). Diet only
and exercise only groups were not considered as single interventions
OXCHECK Study
Methods Primary care practices in urban area
Randomisation by household
Participants Men and women, mean age 49 years (35-64)
No risk screening
N=11,090
Interventions Diet, smoking advice, weight control, alcohol advice, exercise, protocols for management of high blood pressure and
raised blood cholesterol vs. usual care.
Duration 3 years
Outcomes Total mortality and CHD mortality
Systolic blood pressure, diastolic blood pressure, blood cholesterol, smoking prevalence, BMI
Notes Changes in diet and small changes in blood cholesterol, blood pressure and body mass index. No effect on smoking
prevalence. Concluded that primary prevention programmes were able to achieve benefits which were real but must
be weighted against the costs in relation to other priorities. Study was not designed to examine mortality effects but
those randomised to health checks in years 1 to 3 were considered to be intervention group and those randomised to
checks in year 4 were the control group. Deaths up to year 4 were compared
Perez-Stable no prop
Methods Volunteers screened
Randomised by individual stratified for sex, diastolic blood pressure and weight
Participants Men and women aged 18-59
Mild hypertension
N=156
Interventions Nutritionist, health educator, behavioural psychologist, general internist supervised
Aerobic exercise, diet, relaxation 8 weekly meetings, subsequent meeting at 3 months
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Perez-Stable no prop (Continued)
Outcomes No clinical event outcomes
Systolic and diastolic blood pressure, cholesterol, physical activity, self-reported adverse effects dietary intake, weight,
24 hour uring (sodium, potassium)
Follow up at 1 year
Notes Four treatment arms other two had propanolol.
Intervention did not promote persistent behaviour change.
Perez-Stable prop
Methods Volunteers screened
Randomised by individual stratified for sex, diastolic blood pressure and weight
Participants Men and women aged 18-59
Mild hypertension on propanolol
N=156
Interventions Nutritionist, health educator, behavioural psychologist, general internist supervised
Aerobic exercise, diet, relaxation. 8 weekly meetings, subsequent meeting at 3 months
Outcomes No clinical event outcomes
Systolic and diastolic blood pressure, cholesterol, physical activity, self-reported adverse effects, dietary intake, weight,
24 hour uring (sodium, potassium)
Follow up at 1 year
Notes Four treatment arms - other two did not have propanolol.
Intervention did not promote persistent behaviour change.
Stamler 1989
Methods Worksite screening.
Randomisation of individuals
Participants Volunteers from worksites, raised body weight, high pulse rate and DBP 80-89mmHg
Men and women, mean age 37.5 (30-44)
N=201
Interventions Diet, weight control, exercise, alcohol
Duration 5 years
Outcomes No clinical event outcomes
Systolic BP, diastolic BP
Notes Small but significant reduction in blood pressure; other risk factors not reported. Volunteers who were thought
unlikely to comply with intervention (eg. heavy drinkers, very obese) were excluded from the trial
36Multiple risk factor interventions for primary prevention of coronary heart disease (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Stefanick men
Methods Volunteers screened for HDL and LDL cholesterol
Randomisation by individual
Participants Men aged 30-64, HDL <45mg/dl, LDL 126-189mg/dl
126-209mg/dl N=98
Interventions Individual diet counselling and group education.
Weight loss groups.
Supervised and home-based exercise.
Duration 1 year
Outcomes No clinical event outcomes. Diet assessment, body weight, exercise tests, CHD risk factors
Notes Concluded that diet and aerobic exercise was effective in reducing LDL cholesterol
Stefanick women
Methods Volunteers screened for HDL and LDL cholesterol
Randomisation by individual
Participants Post-menopausal women aged 45-64, HDL <60mg/dl, LDL N=89
Interventions Individual diet counselling and group education.
Weight loss groups.
Supervised and home-based exercise.
Duration 1 year
Outcomes No clinical event outcomes. Diet assessment, body weight, exercise tests, CHD risk factors
Notes Concluded that diet and aerobic exercise was effective in reducing LDL cholesterol
Swedish RIS
Methods Clinic attending hypertensives
Randomisation by individual after stratification by serum cholesterol, smoking habit and target organ damage
Participants All men, age 50-72 years
N=508
Interventions Smoking advice + nicotine gum, dietary habits, weight control, spouse involved. Lipid lowering drugs used in needed.
vs. usual care. All patients on antihypertensive medication
Duration 6 years
Outcomes Total mortality, CHD and stroke mortality
Non-fatal myocardial infarction, stroke, new onsets of claudication and angina
Systolic blood pressure, diastolic blood pressure, blood cholesterol, (HDL, LDL), smoking prevalence, body weight,
BMI, blood glucose, heart rate, gGT, HbA1c
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Swedish RIS (Continued)
Notes Significant reductions in blood cholesterol and smoking were achieved. No changes in diastolic blood pressure and
HbA1c. Stroke incidence reduced in intervention group
Take Heart
Methods Workplace screening. Matched pairs of worksites randomised. Unit of analysis was worksite
Participants Men and women mean age 40 (17-73). N=1977
Interventions Stage of change model used; motivational, educational, workplace environment and community reinforcement; focus
on smoking and food choices. Duration 18 months
Outcomes Smoking, blood cholesterol, dietary intake.
Notes Despite documented implementation of interventions no evidence that changes in smoking, cholesterol concentration
of dietary intakes were greater than improvements associated with secular trends observed in control sites. Large
variation in rates of stopping smoking between sites suggested variable use and uptake of interventions
The Oslo Study
Methods Population screening.
Selected for raised blood cholesterol.
Randomisation by individual.
Participants Men only, mean age 45.2 (40-49).
N=1232
Interventions Diet and smoking
Duration 5 years
Outcomes Total mortality, CHD mortality, smoking prevalence, blood cholesterol
Notes Reduction in smoking rates and blood cholesterol. Significant reduction in cardiovascular disease events. Concluded
that advice to stop smoking and change eating habits reduces first myocardial infarctions and sudden deaths
Tromso men
Methods Randomisation of individuals at high risk detected by primary care screening
Participants Men and women, age 30-45 years
N=1373
Interventions Physician and dietician counselling of family, diet, smoking advice, exercise
Duration 6 years
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Tromso men (Continued)
Outcomes No clinical event outcomes
Systolic blood pressure, diastolic blood pressure, blood cholesterol, smoking prevalence
Notes Participants showed little interest in group meetings. Small significant reductions in blood cholesterol but no effects
on smoking or blood pressure. Mortality and clinical event follow up is proceding in the trial and lead author has
not yet published data
Tromso wives
Methods Wives of the men randomised in the Tromso trial are considered to be a seperate trial. Randomisation therefore by
husband
Participants Women aged 30-45
N=809
Interventions Physician and dietician counselling on diet, smoking, exercise
Duration 6 years
Outcomes No clinical event data
Systolic blood pressure, diastolic blood pressure, blood cholesterol, smoking prevalence
Notes Mortality data may be available in the future
Uusitupa
Methods Diabetes clinic. Randomisation by individual
Participants Newly diagnosed NIDDM, men and women aged 40-64 years
N=86
Interventions Education on weight reduction, diet, physical activity. Goals and regular monitoring.
Duration 12 months
Outcomes No clinical event data. Weight reduction, normoglycaemia, correction of dislipidaemias, blood pressure
Notes Intervention and control received 3 months basic diabetes education before randomisation
WHLP
Methods Volunteers recruited. Randomisation of individuals
Participants Women aged 44-50
N=535
Interventions Cognitive- behavioural programme with intensive group and individual guidance on diet, exercise and prevention of
weight gain. Duration 4.5 years
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WHLP (Continued)
Outcomes No clinical event outcomes
Systolic blood pressure, diastolic blood pressure, blood LDL and HDL cholesterol
Notes One accidental death. Participants were receptive to preventive approach and were successful in making initial lifestyle
changes
WHO Factories
Methods Worksites in Belgium, Italy, Poland, Spain, UK; randomisation by factory. Unit of analysis was factory
Participants Men only, mean age 48.5 (40-59)
N=63,732
Interventions Diet, smoking, weight, exercise, antihypertensive drugs, mass media
Control factories had usual occupational health service
Duration 6 years
Outcomes Mortality: cause specific
blood pressure, blood cholesterol, smoking rates
Notes Only small reductions in risk factors found. Spanish arm not included in event ascertainment. Belgium arm showed
significant reduction in mortality and was written up seperately. Concluded that advice on risk factor reduction is
effective to the extent that it is taken up and seems to be safe
Wing
Methods Volunteers
Randomisation by individual
Participants Overweight men and women aged 40-55. Non diabetic but with 1 or 2 parents with type 2 diabetes.
N=80
Interventions Multidisciplinary led behavioural strategies. Group and individual education. Low calorie, low fat diet. Supervised
walking and other activities. Duration 2 years
Outcomes No clinical events outcomes. Eating and exercise behaviours, weight, incidence of diabetes, systolic blood pressure,
diastolic blood pressure, cholesterol
Notes
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Andersen 1999 Both groups received an intervention
Basler 1985 Non-random allocation
Blake 1987 No risk factor change measured or reported
Bruno 1983 Six month data not available
Burke 1999 Participants were younger adults
Cambien 1981 Participants were younger adults
Carlberg 1992 No risk factor data measured or reported
Crouch 1986 Control group received some elements of intervention
Da Qing 1997 No risk factor changes reported
Domarkene 1990 Non-random allocation
DPP 1999 Control group received some elements of intervention
Dunn 1997 Both groups recevied an exercise only intervention
Edye 1989 Non-random allocation
Fielding 1994 Control group received some elements of intervention
Fox 1996 Non-random allocation
Frommer 1990 Inadequate randomisation
Fuchs 1993 Both groups received an intervention
Fullard 1987 Non-random allocation
Gemson 1990 Control group received some elements of intervention
Gemson 1995 Control group received some elements of intervention
German 1994 Control group received some elements of intervention
Gomel 1993 Inadequate randomisation
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(Continued)
Gordon 1997 Control group received some elements of intervention
Hanlon 1995 Six month data not available
Haskell 1988 Secondary prevention
Hedberg 1998 Non-randomised allocation
Jula 1990 Inadequate randomisation
Kawakami 1999 Participants were younger adults
Ketola 2001 Mixed primary and secondary prevention
Knappe 1982 Inadequate randomisation
Kreuter 1996 Outcome is contemplation of quitting smoking
Lasater 1986 No risk factor changes measured or reported
Lauritzen 1995 Health screening only
Leighton 1990 Control group received some elements of intervention
Lindahl 1998 Uncontrolled study
Lovibond 1986 Control group received some elements of intervention
Macdonald 1990 RCT assessing simvastatin
Martinez-A 1990 No risk factor changes measured or reported
McCance 1985 Two month follow up
McCann 1997 Control group received some element of the intervention
Meimanaliev 1991 Non-random allocation
Miemanaliev 1993 Non-random allocation
Murray 1986 No control group baseline data available
Nikitin 1991 Non-random allocation
Nisbeth 2000 Participants were younger adults
Nolte 1997 Two month follow up
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(Continued)
Ostwald 1989 Control group received some element of the intervention
Patterson 1988 No risk factor changes measured or reported
Persson 1996 No 6 month follow up data available. After 6 months pharmacological treatment was provided to intervention
group patients (67% on lipid-lowering drugs and 13% on antihypertensives at 1 year)
Pierce 1984 No risk factor change measured or reported
Reid 1995 Control group received some element of the intervention
Robson 1989 No risk factor changes measured or reported
Rosamond 2000 Non-random allocation
Rowland 1994 Non-random allocation
S-E London 1977 Intervention not characterised
Schwandt 1999 Children and families
Smith 1991 Non-random allocation
Steinbach 1982 Non-random allocation
TOMHS 1991 All participants received intervention
TONE 1998 Three month blood pressure follow up
Tsuyuki 1999 Secondary prevention
Velonakis 1999 Non-random allocation
Volozh 1991 Non-random allocation
WHP Numbers in intervention and control group not reported
Wisewoman 1999 Control group received some element of the intervention
Working Well Trial Baseline data only, no follow up
Wu 1999 Non-random allocation
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D A T A A N D A N A L Y S E S
Comparison 1. Multiple risk factor intervention versus control
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total mortality 9 125167 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.96 [0.92, 1.01]
2 Coronary heart disease mortality 9 125167 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.96 [0.89, 1.04]
3 Systolic blood pressure 38 53872 Mean Difference (IV, Fixed, 95% CI) -3.62 [-3.93, -3.31]
4 Diastolic blood pressure 39 64859 Mean Difference (IV, Fixed, 95% CI) -2.76 [-2.93, -2.59]
5 Blood cholesterol 35 66106 Mean Difference (IV, Fixed, 95% CI) -0.07 [-0.08, -0.06]
6 Smoking prevalence 15 48948 Odds Ratio (M-H, Random, 95% CI) 0.81 [0.70, 0.94]
7 Systolic blood pressure
(individual analysis or cluster)
38 53872 Mean Difference (IV, Random, 95% CI) -2.68 [-3.64, -1.72]
7.1 Cluster randomisation -
analysis by cluster
2 19355 Mean Difference (IV, Random, 95% CI) 0.56 [-2.26, 3.38]
7.2 Individual randomisation 32 33157 Mean Difference (IV, Random, 95% CI) -3.24 [-4.16, -2.31]
7.3 Cluster randomisation -
analysis by individual
4 1360 Mean Difference (IV, Random, 95% CI) 0.03 [-3.28, 3.34]
8 Diastolic blood pressure
(individual analysis or cluster)
39 65362 Mean Difference (IV, Random, 95% CI) -2.01 [-2.63, -1.39]
8.1 Cluster randomisation -
analysis by cluster
2 19348 Mean Difference (IV, Random, 95% CI) -0.27 [-0.81, 0.27]
8.2 Individual randomisation 34 44619 Mean Difference (IV, Random, 95% CI) -2.33 [-2.94, -1.72]
8.3 Cluster randomisation -
analysis by individual
4 1395 Mean Difference (IV, Random, 95% CI) -0.00 [-1.07, 1.07]
9 Cholesterol (individual analysis
or cluster)
35 66106 Mean Difference (IV, Random, 95% CI) -0.25 [-0.35, -0.15]
9.1 Cluster randomisation -
analysis by cluster
2 18833 Mean Difference (IV, Random, 95% CI) 0.01 [-0.03, 0.05]
9.2 Individual randomisation 30 46775 Mean Difference (IV, Random, 95% CI) -0.29 [-0.40, -0.18]
9.3 Cluster randomisation
(analysis by individual)
3 498 Mean Difference (IV, Random, 95% CI) 0.06 [-0.15, 0.28]
10 Smoking prevalence (individual
analysis or cluster)
15 48948 Odds Ratio (M-H, Random, 95% CI) 0.81 [0.70, 0.94]
10.1 Cluster randomisation -
analysis by cluster
1 520 Odds Ratio (M-H, Random, 95% CI) 0.43 [0.28, 0.64]
10.2 Individual randomisation 12 29508 Odds Ratio (M-H, Random, 95% CI) 0.82 [0.70, 0.95]
10.3 Cluster randomisation -
analysis by individual
2 18920 Odds Ratio (M-H, Random, 95% CI) 0.99 [0.90, 1.08]
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Analysis 1.1. Comparison 1 Multiple risk factor intervention versus control, Outcome 1 Total mortality.
Review: Multiple risk factor interventions for primary prevention of coronary heart disease
Comparison: 1 Multiple risk factor intervention versus control
Outcome: 1 Total mortality
Study or subgroup Intervention Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
CELL Study 2/339 1/320 0.0 % 1.84 [ 0.19, 17.80 ]
Finnish men 10/612 5/610 0.2 % 1.96 [ 0.71, 5.41 ]
Gothenberg Study 1293/10004 2636/20018 44.0 % 0.98 [ 0.91, 1.05 ]
HDFP trial 349/5485 419/5455 10.3 % 0.82 [ 0.71, 0.95 ]
Johns Hopkins 35/350 11/50 0.3 % 0.31 [ 0.12, 0.78 ]
MRFIT Study 265/6428 260/6438 7.3 % 1.02 [ 0.86, 1.22 ]
OXCHECK Study 146/8307 40/2783 2.0 % 1.21 [ 0.87, 1.70 ]
Swedish RIS 41/253 64/255 1.2 % 0.58 [ 0.38, 0.89 ]
WHO Factories 1325/30489 1186/26971 34.7 % 0.99 [ 0.91, 1.07 ]
Total (95% CI) 62267 62900 100.0 % 0.96 [ 0.92, 1.01 ]
Total events: 3466 (Intervention), 4622 (Control)
Heterogeneity: Chi2 = 20.94, df = 8 (P = 0.01); I2 =62%
Test for overall effect: Z = 1.54 (P = 0.12)
Test for subgroup differences: Not applicable
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Analysis 1.2. Comparison 1 Multiple risk factor intervention versus control, Outcome 2 Coronary heart
disease mortality.
Review: Multiple risk factor interventions for primary prevention of coronary heart disease
Comparison: 1 Multiple risk factor intervention versus control
Outcome: 2 Coronary heart disease mortality
Study or subgroup Intervention Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
CELL Study 2/339 1/320 0.1 % 1.84 [ 0.19, 17.80 ]
Finnish men 4/612 1/610 0.2 % 3.32 [ 0.57, 19.23 ]
Gothenberg Study 462/10004 923/20018 45.2 % 1.00 [ 0.89, 1.12 ]
HDFP trial 131/5485 148/5455 10.5 % 0.88 [ 0.69, 1.11 ]
Johns Hopkins 23/350 8/50 0.5 % 0.27 [ 0.09, 0.81 ]
MRFIT Study 115/6428 124/6438 9.0 % 0.93 [ 0.72, 1.20 ]
OXCHECK Study 52/8307 13/2783 1.9 % 1.31 [ 0.75, 2.30 ]
Swedish RIS 17/253 23/255 1.4 % 0.73 [ 0.38, 1.39 ]
WHO Factories 428/30489 398/26971 31.2 % 0.95 [ 0.83, 1.09 ]
Total (95% CI) 62267 62900 100.0 % 0.96 [ 0.89, 1.04 ]
Total events: 1234 (Intervention), 1639 (Control)
Heterogeneity: Chi2 = 10.39, df = 8 (P = 0.24); I2 =23%
Test for overall effect: Z = 0.98 (P = 0.33)
Test for subgroup differences: Not applicable
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Analysis 1.3. Comparison 1 Multiple risk factor intervention versus control, Outcome 3 Systolic blood
pressure.
Review: Multiple risk factor interventions for primary prevention of coronary heart disease
Comparison: 1 Multiple risk factor intervention versus control
Outcome: 3 Systolic blood pressure
Study or subgroup Intervention Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Aberg men 79 3.3 (16.3) 80 1.7 (16.21) 0.4 % 1.60 [ -3.45, 6.65 ]
Aberg women 114 4.4 (17.83) 80 0.2 (19.02) 0.3 % 4.20 [ -1.10, 9.50 ]
Abingdon 167 -6.9 (14.6) 168 -5.2 (15.76) 0.9 % -1.70 [ -4.95, 1.55 ]
Applegate 1992 21 -8.7 (11.7) 26 -4.5 (9.7) 0.2 % -4.20 [ -10.44, 2.04 ]
Blumenthal 2000 46 -7.4 (9.31) 22 -0.9 (9.31) 0.4 % -6.50 [ -11.23, -1.77 ]
CELL Study 292 -1.2 (14.7) 310 0 (14.7) 1.7 % -1.20 [ -3.55, 1.15 ]
Change of Heart 165 4.3 (15.4) 339 1.8 (21.61) 0.9 % 2.50 [ -0.79, 5.79 ]
Family Heart - men 1767 -7.3 (19.23) 2174 0 (19.23) 6.6 % -7.30 [ -8.51, -6.09 ]
Family Heart - women 1217 -6.2 (20.43) 1402 0 (20.43) 3.9 % -6.20 [ -7.77, -4.63 ]
FARIS men 219 -4.4 (15.38) 223 -0.6 (15.38) 1.2 % -3.80 [ -6.67, -0.93 ]
FARIS women 315 -3.9 (15.38) 343 -0.7 (15.38) 1.7 % -3.20 [ -5.55, -0.85 ]
Finnish DPS 256 -5 (14) 250 -1 (15) 1.5 % -4.00 [ -6.53, -1.47 ]
Finnish men 575 -10 (18) 580 -4 (16) 2.5 % -6.00 [ -7.96, -4.04 ]
Given 1984 62 -9.85 (12.7) 24 -4.79 (12.61) 0.3 % -5.06 [ -11.01, 0.89 ]
Gothenberg Study 1464 -2 (20) 1404 0 (20) 4.5 % -2.00 [ -3.46, -0.54 ]
Hellenius 39 -4 (12.6) 39 -1 (12.2) 0.3 % -3.00 [ -8.50, 2.50 ]
Iso 53 -13.2 (11.52) 55 -17.4 (14.02) 0.4 % 4.20 [ -0.63, 9.03 ]
Jalkanen 1991 24 -8 (18.68) 25 -5 (18.33) 0.1 % -3.00 [ -13.37, 7.37 ]
Lin 1996 471 -1 (18.52) 426 1 (19.52) 1.5 % -2.00 [ -4.50, 0.50 ]
Lindahl 1999 93 -4.9 (19.3) 93 1.3 (18.3) 0.3 % -6.20 [ -11.61, -0.79 ]
Meland 1997 58 -4 (23.31) 52 0 (22.08) 0.1 % -4.00 [ -12.49, 4.49 ]
MRFIT Study 5740 -13.9 (13.23) 5633 -8.6 (15.27) 34.9 % -5.30 [ -5.83, -4.77 ]
Nilsson 1992 31 -7.7 (17.77) 32 -3.8 (19.3) 0.1 % -3.90 [ -13.06, 5.26 ]
Nilsson 2001 43 -3.7 (20.31) 46 -1.2 (17.9) 0.2 % -2.50 [ -10.48, 5.48 ]
Oldroyd 35 -7.9 (16.7) 32 -0.27 (14.3) 0.2 % -7.63 [ -15.06, -0.20 ]
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(. . . Continued)
Study or subgroup Intervention Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Oslo Diet Exercise 65 -5.9 (8.87) 43 -0.5 (11.15) 0.6 % -5.40 [ -9.37, -1.43 ]
OXCHECK Study 2205 -2.5 (19.3) 1916 0 (20.4) 6.5 % -2.50 [ -3.72, -1.28 ]
Perez-Stable no prop 72 -9 (12.99) 72 -6.7 (13.2) 0.5 % -2.30 [ -6.58, 1.98 ]
Perez-Stable prop 74 -8.3 (13.39) 73 -11.6 (13.3) 0.5 % 3.30 [ -1.01, 7.61 ]
Stamler 1989 102 -2.6 (6.4) 99 -1.3 (6.1) 3.2 % -1.30 [ -3.03, 0.43 ]
Stefanick men 48 -3 (6.8) 46 0.3 (7.9) 1.1 % -3.30 [ -6.29, -0.31 ]
Stefanick women 43 -3.1 (8.4) 45 -2.4 (7.6) 0.9 % -0.70 [ -4.05, 2.65 ]
Swedish RIS 235 -2 (18.4) 227 -0.2 (20.5) 0.8 % -1.80 [ -5.36, 1.76 ]
Tromso men 525 0.5 (15.6) 535 1.1 (16.5) 2.6 % -0.60 [ -2.53, 1.33 ]
Tromso wives 422 -2.16 (15.8) 387 2.1 (16.5) 1.9 % -4.26 [ -6.49, -2.03 ]
WHLP 253 -3.5 (12.18) 267 -1.2 (9.21) 2.8 % -2.30 [ -4.16, -0.44 ]
WHO Factories 16949 2.67 (18.09) 1902 3.18 (18.14) 13.1 % -0.51 [ -1.37, 0.35 ]
Wing 32 -4.8 (15) 31 -1.5 (12) 0.2 % -3.30 [ -10.00, 3.40 ]
Total (95% CI) 34371 19501 100.0 % -3.62 [ -3.93, -3.31 ]
Heterogeneity: Chi2 = 229.68, df = 37 (P<0.00001); I2 =84%
Test for overall effect: Z = 22.84 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.4. Comparison 1 Multiple risk factor intervention versus control, Outcome 4 Diastolic blood
pressure.
Review: Multiple risk factor interventions for primary prevention of coronary heart disease
Comparison: 1 Multiple risk factor intervention versus control
Outcome: 4 Diastolic blood pressure
Study or subgroup Intervention Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Aberg men 79 2 (7.81) 80 1.6 (7.77) 0.5 % 0.40 [ -2.02, 2.82 ]
Aberg women 114 1.3 (9.11) 115 0.8 (8.46) 0.5 % 0.50 [ -1.78, 2.78 ]
Abingdon 167 -4.61 (9.29) 168 -2.9 (9.98) 0.7 % -1.71 [ -3.77, 0.35 ]
Applegate 1992 21 -6.8 (1.7) 26 -1.9 (3.6) 1.2 % -4.90 [ -6.46, -3.34 ]
Blumenthal 2000 46 -5.6 (7.56) 22 -1.4 (7.56) 0.2 % -4.20 [ -8.04, -0.36 ]
CELL Study 292 -0.1 (8.3) 310 0 (9.1) 1.5 % -0.10 [ -1.49, 1.29 ]
Change of Heart 165 0.7 (15.4) 338 1 (9.43) 0.4 % -0.30 [ -2.86, 2.26 ]
Family Heart - men 1767 -3.5 (11.43) 2174 0 (11.43) 5.5 % -3.50 [ -4.22, -2.78 ]
Family Heart - women 1217 -3 (11.33) 1402 0 (11.33) 3.7 % -3.00 [ -3.87, -2.13 ]
FARIS men 219 -1 (9.95) 223 1 (9.95) 0.8 % -2.00 [ -3.86, -0.14 ]
FARIS women 315 -1.1 (9.95) 343 -0.3 (9.95) 1.2 % -0.80 [ -2.32, 0.72 ]
Finnish DPS 256 -5 (9) 250 -3 (9) 1.1 % -2.00 [ -3.57, -0.43 ]
Finnish men 575 -8 (10) 580 -3 (10) 2.1 % -5.00 [ -6.15, -3.85 ]
Given 1984 62 -6.4 (6.99) 24 -2.42 (4.9) 0.4 % -3.98 [ -6.60, -1.36 ]
Gothenberg Study 1464 -1 (10) 1404 0 (10) 5.3 % -1.00 [ -1.73, -0.27 ]
HDFP trial 5485 -17 (10) 5455 -12.1 (10) 20.1 % -4.90 [ -5.27, -4.53 ]
Hellenius 39 -2 (7.7) 39 -1 (8.3) 0.2 % -1.00 [ -4.55, 2.55 ]
Iso 53 -5.1 (8.39) 55 -4.7 (9.06) 0.3 % -0.40 [ -3.69, 2.89 ]
Jalkanen 1991 24 -11 (9.16) 25 -11 (7) 0.1 % 0.0 [ -4.58, 4.58 ]
Lin 1996 471 -2 (11) 426 -2 (11.53) 1.3 % 0.0 [ -1.48, 1.48 ]
Lindahl 1999 93 -3.2 (9.6) 93 -0.8 (9.6) 0.4 % -2.40 [ -5.16, 0.36 ]
Meland 1997 58 -3 (11.66) 52 0 (11.04) 0.2 % -3.00 [ -7.24, 1.24 ]
MRFIT Study 5754 -10.2 (7.88) 5638 -7.1 (9.22) 28.3 % -3.10 [ -3.42, -2.78 ]
Nilsson 1992 31 -6.1 (6.2) 32 -4 (8.23) 0.2 % -2.10 [ -5.69, 1.49 ]
Nilsson 2001 43 -5.7 (10.71) 46 -0.4 (9.56) 0.2 % -5.30 [ -9.53, -1.07 ]
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Study or subgroup Intervention Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Oldroyd 35 -2.9 (9.9) 32 1.9 (10) 0.1 % -4.80 [ -9.57, -0.03 ]
Oslo Diet Exercise 65 -5.2 (7.26) 43 -0.7 (8.52) 0.3 % -4.50 [ -7.60, -1.40 ]
OXCHECK Study 2205 -1.5 (11.6) 1916 0 (11.7) 5.5 % -1.50 [ -2.21, -0.79 ]
Perez-Stable no prop 72 -5 (9.09) 72 -5.8 (9.09) 0.3 % 0.80 [ -2.17, 3.77 ]
Perez-Stable prop 74 -8.2 (9.66) 73 -8.5 (9.15) 0.3 % 0.30 [ -2.74, 3.34 ]
Stamler 1989 102 -1.3 (4.7) 99 -0.1 (4.9) 1.6 % -1.20 [ -2.53, 0.13 ]
Stefanick men 48 -3 (6.6) 46 1.8 (6.1) 0.4 % -4.80 [ -7.37, -2.23 ]
Stefanick women 43 -2.7 (4.6) 45 -0.6 (5.9) 0.6 % -2.10 [ -4.30, 0.10 ]
Swedish RIS 235 -4.9 (9.1) 227 -3.8 (9.6) 1.0 % -1.10 [ -2.81, 0.61 ]
Tromso men 525 -4 (10.6) 535 -3.6 (10.5) 1.7 % -0.40 [ -1.67, 0.87 ]
Tromso wives 422 -2.13 (10.3) 387 1.23 (10.4) 1.4 % -3.36 [ -4.79, -1.93 ]
WHLP 253 -2.2 (10.48) 267 -0.09 (6.92) 1.2 % -2.11 [ -3.65, -0.57 ]
WHO Factories 16948 1.41 (12.29) 1897 1.68 (11.64) 9.1 % -0.27 [ -0.83, 0.29 ]
Wing 32 -0.2 (10.5) 31 2 (8) 0.1 % -2.20 [ -6.80, 2.40 ]
Total (95% CI) 39869 24990 100.0 % -2.76 [ -2.93, -2.59 ]
Heterogeneity: Chi2 = 366.47, df = 38 (P<0.00001); I2 =90%
Test for overall effect: Z = 32.22 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.5. Comparison 1 Multiple risk factor intervention versus control, Outcome 5 Blood cholesterol.
Review: Multiple risk factor interventions for primary prevention of coronary heart disease
Comparison: 1 Multiple risk factor intervention versus control
Outcome: 5 Blood cholesterol
Study or subgroup Intervention Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Aberg men 79 0.3 (1.1) 80 0.1 (1.1) 0.1 % 0.20 [ -0.14, 0.54 ]
Aberg women 114 0.4 (1.35) 115 0.3 (1.1) 0.1 % 0.10 [ -0.22, 0.42 ]
Abingdon 167 -0.2 (0.89) 166 -0.18 (0.9) 0.4 % -0.02 [ -0.21, 0.17 ]
CELL Study 292 -0.15 (0.56) 310 0 (0.65) 1.5 % -0.15 [ -0.25, -0.05 ]
Change of Heart 164 0.31 (0.82) 334 0.33 (1.54) 0.3 % -0.02 [ -0.23, 0.19 ]
Family Heart - men 1767 -0.13 (1.16) 2174 0 (1.16) 2.6 % -0.13 [ -0.20, -0.06 ]
Family Heart - women 1217 -0.09 (1.17) 1402 0 (1.17) 1.7 % -0.09 [ -0.18, 0.00 ]
FARIS men 219 -3 (0.94) 223 0.05 (0.94) 0.5 % -3.05 [ -3.23, -2.87 ]
FARIS women 315 -0.13 (0.94) 343 0.01 (0.94) 0.7 % -0.14 [ -0.28, 0.00 ]
Finnish DPS 256 -0.13 (0.73) 250 -0.1 (0.73) 0.9 % -0.03 [ -0.16, 0.10 ]
Finnish men 575 -0.4 (1) 580 0.05 (0.9) 1.1 % -0.45 [ -0.56, -0.34 ]
Gothenberg Study 1473 -0.01 (1.1) 1404 0 (1.1) 2.1 % -0.01 [ -0.09, 0.07 ]
HDFP trial 5485 -0.39 (1) 5455 -0.39 (1) 9.9 % 0.0 [ -0.04, 0.04 ]
Hellenius 39 -0.45 (0.93) 39 -0.13 (0.9) 0.1 % -0.32 [ -0.73, 0.09 ]
Jalkanen 1991 24 -0.2 (1) 25 0.2 (1) 0.0 % -0.40 [ -0.96, 0.16 ]
Lindahl 1999 93 -0.21 (1.35) 93 -0.06 (0.96) 0.1 % -0.15 [ -0.49, 0.19 ]
Meland 1997 58 0.1 (1.17) 52 0.3 (1.1) 0.1 % -0.20 [ -0.62, 0.22 ]
MRFIT Study 5743 -0.43 (0.99) 5607 -0.3 (1.03) 10.0 % -0.13 [ -0.17, -0.09 ]
Nilsson 2001 43 -0.1 (0.9) 46 0 (1.05) 0.1 % -0.10 [ -0.51, 0.31 ]
Oldroyd 35 -0.16 (0.55) 32 -0.18 (0.59) 0.2 % 0.02 [ -0.25, 0.29 ]
Oslo Diet Exercise 65 -0.48 (0.89) 43 -0.16 (0.59) 0.2 % -0.32 [ -0.60, -0.04 ]
OXCHECK Study 2205 -0.19 (1.1) 1916 0 (1.17) 2.9 % -0.19 [ -0.26, -0.12 ]
Perez-Stable no prop 69 -0.42 (1.15) 68 -0.18 (0.98) 0.1 % -0.24 [ -0.60, 0.12 ]
Perez-Stable prop 67 -0.32 (0.81) 67 -0.25 (0.86) 0.2 % -0.07 [ -0.35, 0.21 ]
Stefanick men 48 -0.54 (0.52) 46 -0.1 (0.56) 0.3 % -0.44 [ -0.66, -0.22 ]
Stefanick women 43 -0.46 (0.56) 45 -0.03 (0.51) 0.3 % -0.43 [ -0.65, -0.21 ]
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Study or subgroup Intervention Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Swedish RIS 235 -0.78 (1.12) 227 -0.39 (0.92) 0.4 % -0.39 [ -0.58, -0.20 ]
Take Heart 1057 0.02 (0.2) 920 0.01 (0.18) 49.3 % 0.01 [ -0.01, 0.03 ]
The Oslo Study 604 -0.92 (0.7) 628 -0.39 (0.7) 2.3 % -0.53 [ -0.61, -0.45 ]
Tromso men 525 -0.41 (1.15) 535 -0.25 (1.2) 0.7 % -0.16 [ -0.30, -0.02 ]
Tromso wives 422 0.06 (1.27) 387 0.14 (1.34) 0.4 % -0.08 [ -0.26, 0.10 ]
Uusitupa 38 -0.1 (0.31) 40 0.1 (0.97) 0.1 % -0.20 [ -0.52, 0.12 ]
WHLP 253 -0.34 (0.61) 267 0.03 (0.21) 2.2 % -0.37 [ -0.45, -0.29 ]
WHO Factories 16481 0.09 (0.89) 1854 0.08 (0.86) 8.1 % 0.01 [ -0.03, 0.05 ]
Wing 32 0.09 (0.67) 31 0.18 (0.53) 0.2 % -0.09 [ -0.39, 0.21 ]
Total (95% CI) 40302 25804 100.0 % -0.07 [ -0.08, -0.06 ]
Heterogeneity: Chi2 = 1536.07, df = 34 (P<0.00001); I2 =98%
Test for overall effect: Z = 11.28 (P < 0.00001)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
52Multiple risk factor interventions for primary prevention of coronary heart disease (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.6. Comparison 1 Multiple risk factor intervention versus control, Outcome 6 Smoking
prevalence.
Review: Multiple risk factor interventions for primary prevention of coronary heart disease
Comparison: 1 Multiple risk factor intervention versus control
Outcome: 6 Smoking prevalence
Study or subgroup Intervention Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Abingdon 46/168 42/167 4.6 % 1.12 [ 0.69, 1.83 ]
CELL Study 139/292 148/310 6.5 % 0.99 [ 0.72, 1.37 ]
Change of Heart 40/169 148/351 5.4 % 0.43 [ 0.28, 0.64 ]
Family Heart - men 337/1767 500/2174 8.4 % 0.79 [ 0.68, 0.92 ]
Family Heart - women 215/1217 301/1402 8.0 % 0.78 [ 0.65, 0.95 ]
Finnish men 125/575 131/580 7.0 % 0.95 [ 0.72, 1.26 ]
Gothenberg Study 691/1473 699/1404 8.5 % 0.89 [ 0.77, 1.03 ]
Meland 1997 35/58 30/52 2.7 % 1.12 [ 0.52, 2.39 ]
MRFIT Study 1847/5754 2554/5638 9.1 % 0.57 [ 0.53, 0.62 ]
Nilsson 2001 17/43 27/46 2.3 % 0.46 [ 0.20, 1.07 ]
OXCHECK Study 544/2205 506/1916 8.6 % 0.91 [ 0.79, 1.05 ]
Swedish RIS 55/253 70/255 5.5 % 0.73 [ 0.49, 1.10 ]
Tromso men 247/525 284/535 7.5 % 0.79 [ 0.62, 1.00 ]
Tromso wives 186/422 178/387 7.0 % 0.93 [ 0.70, 1.22 ]
WHO Factories 7910/16908 897/1902 9.0 % 0.98 [ 0.90, 1.08 ]
Total (95% CI) 31829 17119 100.0 % 0.81 [ 0.70, 0.94 ]
Total events: 12434 (Intervention), 6515 (Control)
Heterogeneity: Tau2 = 0.06; Chi2 = 113.62, df = 14 (P<0.00001); I2 =88%
Test for overall effect: Z = 2.77 (P = 0.0056)
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Analysis 1.7. Comparison 1 Multiple risk factor intervention versus control, Outcome 7 Systolic blood
pressure (individual analysis or cluster).
Review: Multiple risk factor interventions for primary prevention of coronary heart disease
Comparison: 1 Multiple risk factor intervention versus control
Outcome: 7 Systolic blood pressure (individual analysis or cluster)
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Cluster randomisation - analysis by cluster
Change of Heart 165 4.3 (15.4) 339 1.8 (21.61) 2.8 % 2.50 [ -0.79, 5.79 ]
WHO Factories 16949 2.67 (18.09) 1902 3.18 (18.14) 4.1 % -0.51 [ -1.37, 0.35 ]
Subtotal (95% CI) 17114 2241 6.9 % 0.56 [ -2.26, 3.38 ]
Heterogeneity: Tau2 = 3.03; Chi2 = 3.01, df = 1 (P = 0.08); I2 =67%
Test for overall effect: Z = 0.39 (P = 0.70)
2 Individual randomisation
Abingdon 167 -6.9 (14.6) 168 -5.2 (15.76) 2.8 % -1.70 [ -4.95, 1.55 ]
Applegate 1992 21 -8.7 (11.7) 26 -4.5 (9.7) 1.5 % -4.20 [ -10.44, 2.04 ]
Blumenthal 2000 46 -7.4 (9.31) 22 -0.9 (9.31) 2.1 % -6.50 [ -11.23, -1.77 ]
CELL Study 292 -1.2 (14.7) 310 0 (14.7) 3.4 % -1.20 [ -3.55, 1.15 ]
Family Heart - men 1767 -7.3 (19.23) 2174 0 (19.23) 3.9 % -7.30 [ -8.51, -6.09 ]
Family Heart - women 1217 -6.2 (20.43) 1402 0 (20.43) 3.8 % -6.20 [ -7.77, -4.63 ]
FARIS men 219 -4.4 (15.38) 223 -0.6 (15.38) 3.1 % -3.80 [ -6.67, -0.93 ]
FARIS women 315 -3.9 (15.38) 343 -0.7 (15.38) 3.4 % -3.20 [ -5.55, -0.85 ]
Finnish DPS 256 -5 (14) 250 -1 (15) 3.3 % -4.00 [ -6.53, -1.47 ]
Finnish men 575 -10 (18) 580 -4 (16) 3.6 % -6.00 [ -7.96, -4.04 ]
Given 1984 62 -9.85 (12.7) 24 -4.79 (12.61) 1.6 % -5.06 [ -11.01, 0.89 ]
Gothenberg Study 1464 -2 (20) 1404 0 (20) 3.8 % -2.00 [ -3.46, -0.54 ]
Hellenius 39 -4 (12.6) 39 -1 (12.2) 1.8 % -3.00 [ -8.50, 2.50 ]
Iso 53 -13.2 (11.52) 55 -17.4 (14.02) 2.0 % 4.20 [ -0.63, 9.03 ]
Jalkanen 1991 24 -8 (18.68) 25 -5 (18.33) 0.7 % -3.00 [ -13.37, 7.37 ]
Lindahl 1999 93 -4.9 (19.3) 93 1.3 (18.3) 1.8 % -6.20 [ -11.61, -0.79 ]
MRFIT Study 5740 -13.9 (13.23) 5633 -8.6 (15.27) 4.2 % -5.30 [ -5.83, -4.77 ]
Nilsson 1992 31 -7.7 (17.77) 32 -3.8 (19.3) 0.9 % -3.90 [ -13.06, 5.26 ]
Nilsson 2001 43 -3.7 (20.31) 46 -1.2 (17.9) 1.1 % -2.50 [ -10.48, 5.48 ]
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Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Oldroyd 35 -7.9 (16.7) 32 -0.27 (14.3) 1.2 % -7.63 [ -15.06, -0.20 ]
Oslo Diet Exercise 65 -5.9 (8.87) 43 -0.5 (11.15) 2.5 % -5.40 [ -9.37, -1.43 ]
OXCHECK Study 2205 -2.5 (19.3) 1916 0 (20.4) 3.9 % -2.50 [ -3.72, -1.28 ]
Perez-Stable no prop 72 -9 (12.99) 72 -6.7 (13.2) 2.3 % -2.30 [ -6.58, 1.98 ]
Perez-Stable prop 74 -8.3 (13.39) 73 -11.6 (13.3) 2.3 % 3.30 [ -1.01, 7.61 ]
Stamler 1989 102 -2.6 (6.4) 99 -1.3 (6.1) 3.7 % -1.30 [ -3.03, 0.43 ]
Stefanick men 48 -3 (6.8) 46 0.3 (7.9) 3.0 % -3.30 [ -6.29, -0.31 ]
Stefanick women 43 -3.1 (8.4) 45 -2.4 (7.6) 2.8 % -0.70 [ -4.05, 2.65 ]
Swedish RIS 235 -2 (18.4) 227 -0.2 (20.5) 2.7 % -1.80 [ -5.36, 1.76 ]
Tromso men 525 0.5 (15.6) 535 1.1 (16.5) 3.6 % -0.60 [ -2.53, 1.33 ]
Tromso wives 422 -2.16 (15.8) 387 2.1 (16.5) 3.4 % -4.26 [ -6.49, -2.03 ]
WHLP 253 -3.5 (12.18) 267 -1.2 (9.21) 3.6 % -2.30 [ -4.16, -0.44 ]
Wing 32 -4.8 (15) 31 -1.5 (12) 1.4 % -3.30 [ -10.00, 3.40 ]
Subtotal (95% CI) 16535 16622 85.1 % -3.24 [ -4.16, -2.31 ]
Heterogeneity: Tau2 = 4.03; Chi2 = 138.58, df = 31 (P<0.00001); I2 =78%
Test for overall effect: Z = 6.88 (P < 0.00001)
3 Cluster randomisation - analysis by individual
Aberg men 79 3.3 (16.3) 80 1.7 (16.21) 1.9 % 1.60 [ -3.45, 6.65 ]
Aberg women 114 4.4 (17.83) 80 0.2 (19.02) 1.8 % 4.20 [ -1.10, 9.50 ]
Lin 1996 471 -1 (18.52) 426 1 (19.52) 3.3 % -2.00 [ -4.50, 0.50 ]
Meland 1997 58 -4 (23.31) 52 0 (22.08) 1.0 % -4.00 [ -12.49, 4.49 ]
Subtotal (95% CI) 722 638 8.1 % 0.03 [ -3.28, 3.34 ]
Heterogeneity: Tau2 = 5.26; Chi2 = 5.70, df = 3 (P = 0.13); I2 =47%
Test for overall effect: Z = 0.02 (P = 0.98)
Total (95% CI) 34371 19501 100.0 % -2.68 [ -3.64, -1.72 ]
Heterogeneity: Tau2 = 5.73; Chi2 = 229.68, df = 37 (P<0.00001); I2 =84%
Test for overall effect: Z = 5.45 (P < 0.00001)
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Analysis 1.8. Comparison 1 Multiple risk factor intervention versus control, Outcome 8 Diastolic blood
pressure (individual analysis or cluster).
Review: Multiple risk factor interventions for primary prevention of coronary heart disease
Comparison: 1 Multiple risk factor intervention versus control
Outcome: 8 Diastolic blood pressure (individual analysis or cluster)
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Cluster randomisation - analysis by cluster
Change of Heart 165 0.7 (15.4) 338 1 (9.43) 2.2 % -0.30 [ -2.86, 2.26 ]
WHO Factories 16948 1.41 (12.29) 1897 1.68 (11.64) 3.5 % -0.27 [ -0.83, 0.29 ]
Subtotal (95% CI) 17113 2235 5.8 % -0.27 [ -0.81, 0.27 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 0.98 (P = 0.33)
2 Individual randomisation
Abingdon 167 -4.61 (9.29) 168 -2.9 (9.98) 2.6 % -1.71 [ -3.77, 0.35 ]
Applegate 1992 21 -6.8 (1.7) 26 -1.9 (3.6) 2.9 % -4.90 [ -6.46, -3.34 ]
Blumenthal 2000 46 -5.6 (7.56) 22 -1.4 (7.56) 1.5 % -4.20 [ -8.04, -0.36 ]
CELL Study 292 -0.1 (8.3) 310 0 (9.1) 3.1 % -0.10 [ -1.49, 1.29 ]
Change of Heart 165 0.7 (15.4) 338 1 (9.43) 2.2 % -0.30 [ -2.86, 2.26 ]
Family Heart - men 1767 -3.5 (11.43) 2174 0 (11.43) 3.4 % -3.50 [ -4.22, -2.78 ]
Family Heart - women 1217 -3 (11.33) 1402 0 (11.33) 3.4 % -3.00 [ -3.87, -2.13 ]
FARIS men 219 -1 (9.95) 223 1 (9.95) 2.7 % -2.00 [ -3.86, -0.14 ]
FARIS women 315 -1.1 (9.95) 343 -0.3 (9.95) 3.0 % -0.80 [ -2.32, 0.72 ]
Finnish DPS 256 -5 (9) 250 -3 (9) 2.9 % -2.00 [ -3.57, -0.43 ]
Finnish men 575 -8 (10) 580 -3 (10) 3.2 % -5.00 [ -6.15, -3.85 ]
Given 1984 62 -6.4 (6.99) 24 -2.42 (4.9) 2.2 % -3.98 [ -6.60, -1.36 ]
Gothenberg Study 1464 -1 (10) 1404 0 (10) 3.4 % -1.00 [ -1.73, -0.27 ]
HDFP trial 5485 -17 (10) 5455 -12.1 (10) 3.6 % -4.90 [ -5.27, -4.53 ]
Hellenius 39 -2 (7.7) 39 -1 (8.3) 1.7 % -1.00 [ -4.55, 2.55 ]
Iso 53 -5.1 (8.39) 55 -4.7 (9.06) 1.8 % -0.40 [ -3.69, 2.89 ]
Jalkanen 1991 24 -11 (9.16) 25 -11 (7) 1.2 % 0.0 [ -4.58, 4.58 ]
Lindahl 1999 93 -3.2 (9.6) 93 -0.8 (9.6) 2.1 % -2.40 [ -5.16, 0.36 ]
MRFIT Study 5754 -10.2 (7.88) 5638 -7.1 (9.22) 3.6 % -3.10 [ -3.42, -2.78 ]
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Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Nilsson 1992 31 -6.1 (6.2) 32 -4 (8.23) 1.6 % -2.10 [ -5.69, 1.49 ]
Nilsson 2001 43 -5.7 (10.71) 46 -0.4 (9.56) 1.4 % -5.30 [ -9.53, -1.07 ]
Oldroyd 35 -2.9 (9.9) 32 1.9 (10) 1.2 % -4.80 [ -9.57, -0.03 ]
Oslo Diet Exercise 65 -5.2 (7.26) 43 -0.7 (8.52) 1.9 % -4.50 [ -7.60, -1.40 ]
OXCHECK Study 2205 -1.5 (11.6) 1916 0 (11.7) 3.4 % -1.50 [ -2.21, -0.79 ]
Perez-Stable no prop 72 -5 (9.09) 72 -5.8 (9.09) 2.0 % 0.80 [ -2.17, 3.77 ]
Perez-Stable prop 74 -8.2 (9.66) 73 -8.5 (9.15) 1.9 % 0.30 [ -2.74, 3.34 ]
Stamler 1989 102 -1.3 (4.7) 99 -0.1 (4.9) 3.1 % -1.20 [ -2.53, 0.13 ]
Stefanick men 48 -3 (6.6) 46 1.8 (6.1) 2.2 % -4.80 [ -7.37, -2.23 ]
Stefanick women 43 -2.7 (4.6) 45 -0.6 (5.9) 2.5 % -2.10 [ -4.30, 0.10 ]
Swedish RIS 235 -4.9 (9.1) 227 -3.8 (9.6) 2.8 % -1.10 [ -2.81, 0.61 ]
Tromso men 525 -4 (10.6) 535 -3.6 (10.5) 3.1 % -0.40 [ -1.67, 0.87 ]
Tromso wives 422 -2.13 (10.3) 387 1.23 (10.4) 3.0 % -3.36 [ -4.79, -1.93 ]
WHLP 253 -2.2 (10.48) 267 -0.09 (6.92) 3.0 % -2.11 [ -3.65, -0.57 ]
Wing 32 -0.2 (10.5) 31 2 (8) 1.2 % -2.20 [ -6.80, 2.40 ]
Subtotal (95% CI) 22199 22420 85.1 % -2.33 [ -2.94, -1.72 ]
Heterogeneity: Tau2 = 2.15; Chi2 = 248.11, df = 33 (P<0.00001); I2 =87%
Test for overall effect: Z = 7.45 (P < 0.00001)
3 Cluster randomisation - analysis by individual
Aberg men 79 2 (7.81) 80 1.6 (7.77) 2.3 % 0.40 [ -2.02, 2.82 ]
Aberg women 114 1.3 (9.11) 115 0.8 (8.46) 2.4 % 0.50 [ -1.78, 2.78 ]
Lin 1996 471 -2 (11) 426 -2 (11.53) 3.0 % 0.0 [ -1.48, 1.48 ]
Meland 1997 58 -3 (11.66) 52 0 (11.04) 1.4 % -3.00 [ -7.24, 1.24 ]
Subtotal (95% CI) 722 673 9.1 % 0.00 [ -1.07, 1.07 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.21, df = 3 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 0.00 (P = 1.0)
Total (95% CI) 40034 25328 100.0 % -2.01 [ -2.63, -1.39 ]
Heterogeneity: Tau2 = 2.81; Chi2 = 370.01, df = 39 (P<0.00001); I2 =89%
Test for overall effect: Z = 6.31 (P < 0.00001)
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Analysis 1.9. Comparison 1 Multiple risk factor intervention versus control, Outcome 9 Cholesterol
(individual analysis or cluster).
Review: Multiple risk factor interventions for primary prevention of coronary heart disease
Comparison: 1 Multiple risk factor intervention versus control
Outcome: 9 Cholesterol (individual analysis or cluster)
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Cluster randomisation - analysis by cluster
Change of Heart 164 0.31 (0.82) 334 0.33 (1.54) 2.9 % -0.02 [ -0.23, 0.19 ]
WHO Factories 16481 0.09 (0.89) 1854 0.08 (0.86) 3.3 % 0.01 [ -0.03, 0.05 ]
Subtotal (95% CI) 16645 2188 6.2 % 0.01 [ -0.03, 0.05 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.08, df = 1 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 0.43 (P = 0.67)
2 Individual randomisation
Abingdon 167 -0.2 (0.89) 166 -0.18 (0.9) 3.0 % -0.02 [ -0.21, 0.17 ]
CELL Study 292 -0.15 (0.56) 310 0 (0.65) 3.2 % -0.15 [ -0.25, -0.05 ]
Family Heart - men 1767 -0.13 (1.16) 2174 0 (1.16) 3.3 % -0.13 [ -0.20, -0.06 ]
Family Heart - women 1217 -0.09 (1.17) 1402 0 (1.17) 3.3 % -0.09 [ -0.18, 0.00 ]
FARIS men 219 -3 (0.94) 223 0.05 (0.94) 3.0 % -3.05 [ -3.23, -2.87 ]
FARIS women 315 -0.13 (0.94) 343 0.01 (0.94) 3.1 % -0.14 [ -0.28, 0.00 ]
Finnish DPS 256 -0.13 (0.73) 250 -0.1 (0.73) 3.2 % -0.03 [ -0.16, 0.10 ]
Finnish men 575 -0.4 (1) 580 0.05 (0.9) 3.2 % -0.45 [ -0.56, -0.34 ]
Gothenberg Study 1473 -0.01 (1.1) 1404 0 (1.1) 3.3 % -0.01 [ -0.09, 0.07 ]
HDFP trial 5485 -0.39 (1) 5455 -0.39 (1) 3.3 % 0.0 [ -0.04, 0.04 ]
Hellenius 39 -0.45 (0.93) 39 -0.13 (0.9) 2.1 % -0.32 [ -0.73, 0.09 ]
Jalkanen 1991 24 -0.2 (1) 25 0.2 (1) 1.6 % -0.40 [ -0.96, 0.16 ]
Lindahl 1999 93 -0.21 (1.35) 93 -0.06 (0.96) 2.4 % -0.15 [ -0.49, 0.19 ]
MRFIT Study 5743 -0.43 (0.99) 5607 -0.3 (1.03) 3.3 % -0.13 [ -0.17, -0.09 ]
Nilsson 2001 43 -0.1 (0.9) 46 0 (1.05) 2.1 % -0.10 [ -0.51, 0.31 ]
Oldroyd 35 -0.16 (0.55) 32 -0.18 (0.59) 2.7 % 0.02 [ -0.25, 0.29 ]
Oslo Diet Exercise 65 -0.48 (0.89) 43 -0.16 (0.59) 2.6 % -0.32 [ -0.60, -0.04 ]
OXCHECK Study 2205 -0.19 (1.1) 1916 0 (1.17) 3.3 % -0.19 [ -0.26, -0.12 ]
Perez-Stable no prop 69 -0.42 (1.15) 68 -0.18 (0.98) 2.3 % -0.24 [ -0.60, 0.12 ]
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Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Perez-Stable prop 67 -0.32 (0.81) 67 -0.25 (0.86) 2.6 % -0.07 [ -0.35, 0.21 ]
Stefanick men 48 -0.54 (0.52) 46 -0.1 (0.56) 2.9 % -0.44 [ -0.66, -0.22 ]
Stefanick women 43 -0.46 (0.56) 45 -0.03 (0.51) 2.9 % -0.43 [ -0.65, -0.21 ]
Swedish RIS 235 -0.78 (1.12) 227 -0.39 (0.92) 3.0 % -0.39 [ -0.58, -0.20 ]
Take Heart 1057 0.02 (0.2) 920 0.01 (0.18) 3.3 % 0.01 [ -0.01, 0.03 ]
The Oslo Study 604 -0.92 (0.7) 628 -0.39 (0.7) 3.3 % -0.53 [ -0.61, -0.45 ]
Tromso men 525 -0.41 (1.15) 535 -0.25 (1.2) 3.1 % -0.16 [ -0.30, -0.02 ]
Tromso wives 422 0.06 (1.27) 387 0.14 (1.34) 3.0 % -0.08 [ -0.26, 0.10 ]
Uusitupa 38 -0.1 (0.31) 40 0.1 (0.97) 2.5 % -0.20 [ -0.52, 0.12 ]
WHLP 253 -0.34 (0.61) 267 0.03 (0.21) 3.3 % -0.37 [ -0.45, -0.29 ]
Wing 32 0.09 (0.67) 31 0.18 (0.53) 2.6 % -0.09 [ -0.39, 0.21 ]
Subtotal (95% CI) 23406 23369 86.8 % -0.29 [ -0.40, -0.18 ]
Heterogeneity: Tau2 = 0.09; Chi2 = 1517.13, df = 29 (P<0.00001); I2 =98%
Test for overall effect: Z = 5.04 (P < 0.00001)
3 Cluster randomisation (analysis by individual)
Aberg men 79 0.3 (1.1) 80 0.1 (1.1) 2.4 % 0.20 [ -0.14, 0.54 ]
Aberg women 114 0.4 (1.35) 115 0.3 (1.1) 2.5 % 0.10 [ -0.22, 0.42 ]
Meland 1997 58 0.1 (1.17) 52 0.3 (1.1) 2.1 % -0.20 [ -0.62, 0.22 ]
Subtotal (95% CI) 251 247 6.9 % 0.06 [ -0.15, 0.28 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 2.14, df = 2 (P = 0.34); I2 =7%
Test for overall effect: Z = 0.59 (P = 0.55)
Total (95% CI) 40302 25804 100.0 % -0.25 [ -0.35, -0.15 ]
Heterogeneity: Tau2 = 0.07; Chi2 = 1536.07, df = 34 (P<0.00001); I2 =98%
Test for overall effect: Z = 4.95 (P < 0.00001)
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Analysis 1.10. Comparison 1 Multiple risk factor intervention versus control, Outcome 10 Smoking
prevalence (individual analysis or cluster).
Review: Multiple risk factor interventions for primary prevention of coronary heart disease
Comparison: 1 Multiple risk factor intervention versus control
Outcome: 10 Smoking prevalence (individual analysis or cluster)
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Cluster randomisation - analysis by cluster
Change of Heart 40/169 148/351 5.4 % 0.43 [ 0.28, 0.64 ]
Subtotal (95% CI) 169 351 5.4 % 0.43 [ 0.28, 0.64 ]
Total events: 40 (Treatment), 148 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 4.06 (P = 0.000050)
2 Individual randomisation
Abingdon 46/168 42/167 4.6 % 1.12 [ 0.69, 1.83 ]
CELL Study 139/292 148/310 6.5 % 0.99 [ 0.72, 1.37 ]
Family Heart - men 337/1767 500/2174 8.4 % 0.79 [ 0.68, 0.92 ]
Family Heart - women 215/1217 301/1402 8.0 % 0.78 [ 0.65, 0.95 ]
Finnish men 125/575 131/580 7.0 % 0.95 [ 0.72, 1.26 ]
Gothenberg Study 691/1473 699/1404 8.5 % 0.89 [ 0.77, 1.03 ]
MRFIT Study 1847/5754 2554/5638 9.1 % 0.57 [ 0.53, 0.62 ]
Nilsson 2001 17/43 27/46 2.3 % 0.46 [ 0.20, 1.07 ]
OXCHECK Study 544/2205 506/1916 8.6 % 0.91 [ 0.79, 1.05 ]
Swedish RIS 55/253 70/255 5.5 % 0.73 [ 0.49, 1.10 ]
Tromso men 247/525 284/535 7.5 % 0.79 [ 0.62, 1.00 ]
Tromso wives 186/422 178/387 7.0 % 0.93 [ 0.70, 1.22 ]
Subtotal (95% CI) 14694 14814 83.0 % 0.82 [ 0.70, 0.95 ]
Total events: 4449 (Treatment), 5440 (Control)
Heterogeneity: Tau2 = 0.05; Chi2 = 72.53, df = 11 (P<0.00001); I2 =85%
Test for overall effect: Z = 2.56 (P = 0.010)
3 Cluster randomisation - analysis by individual
Meland 1997 35/58 30/52 2.7 % 1.12 [ 0.52, 2.39 ]
WHO Factories 7910/16908 897/1902 9.0 % 0.98 [ 0.90, 1.08 ]
Subtotal (95% CI) 16966 1954 11.6 % 0.99 [ 0.90, 1.08 ]
Total events: 7945 (Treatment), 927 (Control)
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(. . . Continued)
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Heterogeneity: Tau2 = 0.0; Chi2 = 0.10, df = 1 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 0.28 (P = 0.78)
Total (95% CI) 31829 17119 100.0 % 0.81 [ 0.70, 0.94 ]
Total events: 12434 (Treatment), 6515 (Control)
Heterogeneity: Tau2 = 0.06; Chi2 = 113.62, df = 14 (P<0.00001); I2 =88%
Test for overall effect: Z = 2.77 (P = 0.0056)
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
A D D I T I O N A L T A B L E S
Table 1. MEDLINE search strategy April 1995
randomized controlled trial.pt.
randomized controlled trials/
random-allocation.sh.
double-blind-method.sh.
single-blind-method.sh.
1 or 2 or 3 or 4 or 5
clinical trials.pt.
clinical trials.sh.
clin$ near trial$.ti.
clin$ near trial$.ab.
placebo.sh.
placebo.tw.
random.tw.
7 or 8 or 9 or 10 or 11 or 12 or 13
limit 14 to human
coronary disease.sh.
cerebrovascular disorders.sh.
Table 2. CENTRAL search strategy Issue 3 2001
#1 CARDIOVASCULAR DISEASES
#2 CORONARY DISEASE
#3 cardiovascular
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Table 2. CENTRAL search strategy Issue 3 2001 (Continued)
#4 (coronary near disease*)
#5 (heart near disease*)
#6 HYPERTENSION
#7 hypertension
#8 (atherosclerosis or arteriosclerosis)
#9 (hyperlipidaemia or hyperlipidemia)
#10 ARTERIOSCLEROSIS
#11 CHOLESTEROL
#12 HYPERLIPIDEMIA
#13 cholesterol
#14 (multiple next risk next factor*)
#15 (coronary next risk next factor*)
#16 (#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10)
#17 (#11 or #12 or #13 or #14 or #15)
#18 (#16 or #17)
#19 HEALTH EDUCATION
#20 HEALTH PROMOTION
#21 HEALTH BEHAVIOR
#22 PRIMARY PREVENTION
#23 COUNSELING
#24 counsel*
#25 (health near educat*)
#26 (patient near educat*)
#27 (education* near program*)
#28 (health near promotion*)
#29 (health near behaviour*)
#30 (health near behavior*)
#31 (primary next prevention)
#32 ((multiple next risk) near intervention*)
#33 (multifactor* near intervention*)
#34 (multifactor* near prevention)
#35 ((risk next factor*) near reduc*)
#36 ((risk next factor*) near manag*)
#37 ((risk next factor*) near intervent*)
#38 (lifestyle near intervention*)
#39 (lifestyle near advice)
#40 (life-style near intervention*)
#41 (life-style near advice)
#42 (life-style near alter*)
#43 (lifestyle near alter*)
#44 (lifestyle near educat*)
#45 (life-style near educat*)
#46 (life-style near chang*)
#47 (lifestyle near chang*)
#48 (behavior* near chang*)
#49 (behaviour* near chang*)
#50 ((health next care) near advice)
#51 (healthcare near advice)
#52 nonpharmacologic*
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Table 2. CENTRAL search strategy Issue 3 2001 (Continued)
#53 non-pharmacologic*
#54 (#19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29)
#55 (#30 or #31 or #32 or #33 or #34 or #35 or #36 or #37 or #38 or #39)
#56 (#40 or #41 or #42 or #43 or #44 or #45 or #46 or #47 or #48 or #49 or #50 or #51 or #52 or #53)
#57 ((#54 or #55 or #56)
#58 (#18 and #57)
Table 3. MEDLINE search strategy September 2001
Database: Medline <Mid 1998 to August Week 2 2001>
Search Strategy:
--------------------------------------------------------------------------------
1 cardiovascular diseases/
2 exp coronary disease/
3 hypertension/
4 exp Arteriosclerosis/
5 exp Hyperlipidemia/
6 (cardiovascular adj3 disease$).tw.
7 (cardiovascular adj3 (fit or fitness)).tw.
8 (Coronary adj3 disease$).tw.
9 heart disease$.tw.
10 hypertension.tw.
11 hyperlipid?emia.tw.
12 cholesterol.tw.
13 atherosclerosis.tw.
14 arteriosclerosis.tw.
15 coronary risk factor$.tw.
16 multiple risk factor$.tw.
17 cardiovascular risk factor$.tw.
18 or/1-17
19 health promotion/
20 exp health education/
21 exp health behavior/
22 exp counseling/
23 primary prevention/
24 (multifactor$ adj5 (intervent$ or prevent$)).tw.
25 ((lifestyle or life-style) adj3 (intervention$ or educat$ or advice$ or alter$ or change$)).tw.
26 ((lifestyle or life-style or behavio?r$) adj3 (intervention$ or educat$ or advice$ or alter$ or change$)).tw.
27 ((healthcare or health care) adj3 advice).tw.
28 primary prevention.tw.
29 (risk factor$ adj3 (reduc$ or manage$ or managing or intervent$ or program$)).tw.
30 (educat$ adj3 (program$ or patient$)).tw.
31 ((health or healthcare or health care) adj3 (educat$ or advice or promot$)).tw.
32 (nonpharmacologic$ or non-pharmacologic$).tw.
33 ((lifestyle or life style or life-style or behavio?r$ or risk factor$) adj3 modif$).tw.
34 or/19-33
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Table 3. MEDLINE search strategy September 2001 (Continued)
35 18 and 34
36 randomized controlled trial.pt.
37 controlled clinical trial.pt.
38 Randomized controlled trials/
39 random allocation.sh.
40 double blind method.sh.
41 single-blind method.sh.
42 or/36-41
43 (animal not human).sh.
44 42 not 43
45 clinical trial.pt.
46 exp Clinical trials/
47 (clin$ adj25 trial$).ti,ab.
48 ((singl$ or doubl$ or trebl$ or tripl$) adj (blind$ or mask$)).ti,ab.
49 placebos.sh.
50 placebo$.ti,ab.
51 random$.ti,ab.
52 research design.sh.
53 or/45-52
54 53 not 43
55 54 not 44
56 44 or 54
57 35 and 56
58 limit 57 to yr=2000-2001
Table 4. EMBASE search strategy September 2001
Database: EMBASE <1996 to August Week 2 2001>
Search Strategy:
--------------------------------------------------------------------------------
1 cardiovascular diseases/
2 exp coronary disease/
3 hypertension/
4 exp Arteriosclerosis/
5 exp Hyperlipidemia/
6 (cardiovascular adj3 disease$).tw.
7 (cardiovascular adj3 (fit or fitness)).tw.
8 (Coronary adj3 disease$).tw.
9 heart disease$.tw.
10 hypertension.tw.
11 hyperlipid?emia.tw.
12 cholesterol.tw.
13 atherosclerosis.tw.
14 arteriosclerosis.tw.
15 coronary risk factor$.tw.
16 multiple risk factor$.tw.
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Table 4. EMBASE search strategy September 2001 (Continued)
17 cardovascular risk factor$.tw.
18 or/1-17
19 health promotion/
20 exp health education/
21 exp health behavior/
22 exp counseling/
23 primary prevention/
24 (multifactor$ adj5 (intervent$ or prevent$)).tw.
25 ((lifestyle or life-style) adj3 (intervention$ or educat$ or advice$ or alter$ or change$)).tw.
26 ((lifestyle or life-style or behavio?r$) adj3 (intervention$ or educat$ or advice$ or alter$ or change$)).tw.
27 ((healthcare or health care) adj3 advice).tw.
28 primary prevention.tw.
29 (risk factor$ adj3 (reduc$ or manage$ or managing or intervent$ or program$)).tw.
30 (educat$ adj3 (program$ or patient$)).tw.
31 ((health or healthcare or health care) adj3 (educat$ or advice or promot$)).tw.
32 (nonpharmacologic$ or non-pharmacologic$).tw.
33 ((lifestyle or life style or life-style or behavio?r$ or risk factor$) adj3 modif$).tw.
34 or/19-33
35 18 and 34
36 cardiovascular disease/
37 exp ischemic heart disease/
38 (coronary adj3 disease$).tw.
39 heart disease$.tw.
40 Hypertension/
41 hypertension.tw.
42 (cardiovascular adj3 (disease$ or fit of fitness)).tw.
43 exp arteriosclerosis/
44 exp hyperlipidemia/
45 hyperlipid?emia.tw.
46 cholesterol.tw.
47 arteriosclero$.tw.
48 atherosclero$.tw.
49 coronary risk factor$.tw.
50 multiple risk factor$.tw.
51 cardiovascular risk factor$.tw.
52 or/36-51
53 exp health education/
54 exp health behavior/
55 primary prevention/
56 exp counseling/
57 (multifactor$ adj5 (intervent$ or prevent$)).tw.
58 ((life-style or life style or lifestyle or healthcare or health care) adj3 (intervention$ or educat$ or advice or alter$ or change$)).tw.
59 primary prevention.tw.
60 (risk factor$ adj3 (reduc$ or manage$ or managing or intervent$ or program$)).tw.
61 (educat$ adj3 (program$ or patient$)).tw.
62 (non pharmacologic$ or nonpharmacologic$).tw.
63 (risk factor$ adj3 modif$).tw.
64 ((lifestyle or life-style or life style) adj3 modif$).tw.
65 exp behavior therapy/
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Table 4. EMBASE search strategy September 2001 (Continued)
66 (behavi?r$ adj3 (intervention$ or program$ or modif$ or change$ or alter$)).tw.
67 (promot$ adj3 (health or healthcare or health care)).tw.
68 or/53-67
69 52 and 68
70 random$.tw.
71 randomized controlled trial/
72 trial$.tw.
73 compar$.tw.
74 follow-up.tw.
75 blind$.tw.
76 double blind procedure/
77 placebo$.tw.
78 placebo/
79 doubl$.tw.
80 nonhuman/ not human/
81 exp child/ not exp adult/
82 or/70-79
83 82 and 69
84 83 not (80 or 81)
WH A T ’ S N E W
Last assessed as up-to-date: 17 August 2006.
Date Event Description
9 September 2008 Amended Converted to new review format.
H I S T O R Y
Review first published: Issue 2, 1999
Date Event Description
18 August 2006 New citation required and conclusions have changed Substantive amendment
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